

Enantioselective Synthesis of C-Linked Spiroacetal-Triazoles as Privileged Natural Product-Like Scaffolds

Jui Thiang Brian Kueh, Ka Wai Choi, Margaret A. Brimble*

*School of Chemical Sciences, The University of Auckland,
23 Symonds Street, Auckland, New Zealand.*

E-mail: m.brimble@auckland.ac.nz;

Fax: +64 9 3737422; Tel: +64 9 9238259


Supporting Information

- General Experimental	S2
- Experimental and Characterization data of the intermediates in the synthesis of of acetylenic spiroacetal 11	S3
- ¹ H and ¹³ C NMR spectra of compounds 11 , 17 , 18 , 23 , 24 , 25 and 26	S10
- Experimental and Characterization data for azides 27a-h and intermediates involved in the synthesis of 27a-h	S24
- ¹ H and ¹³ C NMR spectra of compounds 27c , 27d and non-literature intermediates	S30
- Experimental and Characterization data for silyl-protected triazoles 28a-h	S38
- ¹ H and ¹³ C NMR spectra of silyl-protected spiroacetal-triazoles 28a-h	S44
- Experimental and Characterization data for hydroxymethyl spiroacetal-triazoles 10a-h	S60
- ¹ H and ¹³ C NMR spectra hydroxymethyl spiroacetal-triazoles 10a-h	S66

General Experimental


Experiments requiring anhydrous conditions were performed under a dry nitrogen or argon atmosphere using apparatus heated and dried under vacuum and standard techniques in handling air- and/or moisture-sensitive materials unless otherwise stated. Solvents used for reactions and chromatographic purifications were distilled, unless otherwise stated. Commercial reagents were analytical grade or were purified by standard procedures prior to use.¹ Reactions were monitored by thin layer chromatography (TLC) carried out on 0.2 mm Kieselgel F254 (Merck) silica gel plates using UV light as a visualising agent and then stained and developed with heat using either vanillin in ethanolic sulfuric acid, ammonium heptamolybdate and cerium sulfate in aqueous sulfuric acid or potassium permanganate and potassium carbonate in aqueous sodium hydroxide. Separation of mixtures was performed by flash chromatography using 0.063–0.1 mm silica gel with the indicated eluent. Melting points were determined on a Kofler hot stage apparatus and are uncorrected. Optical rotations were measured using a Perkin-Elmer 341 polarimeter at a wavelength of 598 nm and are reported in $10^{-1} \text{ }^\circ\text{C cm}^2 \text{ g}^{-1}$. Infrared spectra were obtained using a Perkin Elmer Spectrum 100 Fourier Transform Infrared spectrometer on a film ATR sampling accessory. Absorption peaks are reported as wavenumbers (ν , cm^{-1}). NMR spectra were recorded on either a Bruker DRX 300 spectrophotometer operating at 300 MHz for ^1H nuclei and 75 MHz for ^{13}C nuclei, or a Bruker DRX400 or a Bruker UltraShield Plus 400 spectrophotometer operating at 400 MHz for ^1H nuclei and 100 MHz for ^{13}C nuclei at ambient temperature. ^1H NMR chemical shifts are reported in parts per million (ppm) relative to the chloroform peak (δ 7.26). ^1H NMR values are reported as chemical shifts δ , relative integral, multiplicity (s, singlet; d, doublet; t, triplet; dd, doublet of doublets; dt, doublet of triplets; td, triplet of doublets; m, multiplet), coupling constant (J , Hz) and assignment. Coupling constants were taken directly from the spectra. ^{13}C NMR chemical shifts are reported in ppm relative to the chloroform peak (δ 77.0). ^{13}C NMR values are reported as chemical shifts δ and assignment. Assignments were made with the aid of DEPT, COSY, HSQC, HMBC and NOESY experiments. Mass spectra were recorded on a VG-70SE mass spectrometer at a nominal accelerating voltage of 70 eV or on a Bruker micrOTOF-Q II mass spectrophotometer by electrospray ionisation in positive mode. Major and significant fragments are quoted in the form x (y), where x is the mass to charge ratio (m/z) and y is the percentage abundance relative to the base peak (100%). High-resolution mass spectra (HRMS) were obtained with a nominal resolution of 5,000 to 10,000.

Experimental and Characterization data of the intermediates in the synthesis of acetylenic spiroacetal **11**



6-(*tert*-Butyldiphenylsilyloxy)-(5*S*)-5-hydroxy-*N*-methoxy-*N*-methylhexanamide (**22**)


To a stirred suspension of *N,O*-dimethylhydroxylamine hydrochloride (2.24 g, 23.0 mmol) in anhydrous CH₂Cl₂ (80 mL) at 0 °C, was added dropwise a solution of (CH₃)₃Al (2.0 M in toluene, 11.5 mL, 23.0 mmol). The mixture was stirred at 0 °C whereupon all of the solids dissolved to give a colourless solution. Whilst maintaining the mixture at 0 °C, a solution of (*S*)-valerolactone **13** (3.98 g, 10.8 mmol) in anhydrous CH₂Cl₂ (40 mL) was added dropwise to give a pale yellow solution that was allowed to warm to RT. After 3.5 h of vigorous stirring, the reaction mixture was carefully poured into a 1:1 ice-cold mixture of saturated NH₄Cl:Rochelle's salt (80 mL) to afford a colourless suspension. Et₂O (60 mL) was added and the suspension stirred vigorously with warming to RT over 45 mins. The layers were separated and the aqueous phase was extracted with Et₂O (2 x 60 mL). The combined organic extracts were dried over MgSO₄ and concentrated *in vacuo* to afford the crude *title compound 22* as a yellow oil (4.64 g, 100%) that was used without further purification. Purification by flash chromatography (30% to 70% EtOAc/*n*-hexane) afforded the *title compound 22* as a faint yellow oil. $[\alpha]_D^{20}$ -2.0 (c 1.00 in CHCl₃); *R_f* (30% EtOAc/*n*-hexane) 0.20, (70% EtOAc/*n*-hexane) 0.55; δ_H (300 MHz, CDCl₃) 1.07 (9H, s, OSiPh₂^{*t*}Bu), 1.43–1.49 (2H, m, 4-H), 1.64–1.81 (2H, m, 3-H), 2.43 (2H, t, ³*J*_{2,3} 7.3 Hz, 2-H), 2.65 (1H, br s, OH), 3.16 (3H, s, NCH₃), 3.51 (1H, dd, ²*J*_{AB} 10.0 and ³*J*_{6A,5} 7.5, 6-H_A), 3.66 (1H, dd, ²*J*_{AB} 10.0 and ³*J*_{6B,5} 3.5 Hz, 6-H_B), 3.66 (3H, s, OCH₃), 3.70–3.78 (1H, m, 5-H) 7.36–7.43 (6H, m, Ph), 7.64–7.67 (4H, m, Ph); δ_C (75 MHz, CDCl₃) 19.2 (C, OSiPh₂^{*t*}Bu), 20.5 (CH₂, C-3), 26.8 (CH₃, OSiPh₂^{*t*}Bu), 31.6 (CH₂, C-2), 32.1 (CH₃, NCH₃), 32.4 (CH₂, C-4), 61.1 (CH₃, OCH₃), 68.0 (CH₂, C-6), 71.6 (CH, C-5), 127.7 (CH, Ph), 129.7 (CH, Ph), 133.2 (C, Ph), 135.5 (CH, Ph), 135.5 (CH, Ph), 174.3 (C, C-1). The ¹H and ¹³C NMR data obtained was in agreement with that reported in the literature.²



(5*S*)-5-(*tert*-Butyl-dimethylsilyloxy)-6-(*tert*-butyldiphenylsilyloxy)-*N*-methoxy-*N*-methylhexanamide (**19**)

To a stirred solution of crude Weinreb alcohol **22** (*ca.* 7.09 g, 16.5 mmol) in anhydrous CH₂Cl₂ (45 mL) in a nitrogen flushed 2-necked round bottom flask, was added imidazole (2.63 g, 38.64 mmol), DMAP (449.0 mg, 3.68 mmol) and TBDMSCl (2.86 g, 19.0 mmol) at RT and the mixture was heated to 45 °C. After 13 h, the reaction mixture was cooled to RT and quenched with saturated NaHCO₃ (35 mL). The aqueous phase was extracted with Et₂O (50 mL, then 2 x 25 mL) and the


combined organic extracts were washed with saturated NaCl (100 mL). The aqueous washing was extracted with Et₂O (2 x 50 mL) and the organic phases were dried over MgSO₄. Concentration of the combined organic phases *in vacuo* gave a thick yellow oil. Purification by flash chromatography twice (5%, 9% to 17% EtOAc/*n*-hexane) gave the *title compound* **19** as a thick pale yellow oil (7.04 g, 78%). $[\alpha]_D^{23}$ -12.6 (c 1.01 in CHCl₃); R_f (17% EtOAc/*n*-hexane) 0.48; δ_H (300 MHz, CDCl₃) -0.07 (3H, s, OSi(CH₃)₂^tBu), 0.01 (3H, s, OSi(CH₃)₂^tBu), 0.84 (9H, s, OSiPh₂^tBu), 1.04 (9H, s, OSiPh₂^tBu), 1.43–1.59 (1H, m, 4-H_A), 1.61–1.76 (3H, m, 3-H and 4-H_B), 2.43 (2H, t, ³J_{2,3} 7.5, 2-H), 3.18 (3H, s, NCH₃), 3.48 (1H, dd, ²J_{AB} 10.5 and ³J_{6A,7} 7.5, 6-H_A), 3.59 (1H, dd, ²J_{AB} 10.5 and ³J_{6A,7} 4.5, 6-H_B), 3.67 (3H, s, OCH₃), 3.71–3.74 (1H, m, 5-H), 7.34–7.45 (6H, m, Ph), 7.65–7.69 (4H, m, Ph); δ_C (75 MHz, CDCl₃) -4.8 (CH₃, OSi(CH₃)₂^tBu), -4.5 (CH₃, OSi(CH₃)₂^tBu), 18.0 (C, OSi(CH₃)₂^tBu), 19.2 (C, OSiPh₂^tBu), 20.4 (CH₂, C-3), 25.9 (CH₃, OSi(CH₃)₂^tBu), 26.9 (CH₃, OSiPh₂^tBu), 32.3 (CH₃ and CH₂, NCH₃ and C-2), 34.1 (CH₂, C-4), 61.2 (CH₃, OCH₃), 67.6 (CH₂, C-6), 72.7 (CH, C-5), 127.6 (CH, Ph), 129.6 (CH, Ph), 133.7 (C, Ph), 133.7 (C, Ph), 135.6 (CH, Ph), 174.6 (C, C-1). The ¹H and ¹³C NMR data obtained was in agreement with that reported in the literature.²



(10S)-10-(tert-Butyldimethylsilyloxy)-11-(tert-butyldiphenylsilyloxy)undec-1-en-6-one (23)


Magnesium turnings (467 mg, 19.21 mmol) were stirred vigorously under an argon atmosphere overnight. To this was added anhydrous Et₂O (2 mL) and a single crystal of I₂. The mixture was heated gently and stirred until the orange colour faded. 5-Bromo-1-pentene (1.1 mL, 9.30 mmol) was added dropwise with gentle heating whereupon the reaction was initiated. The reaction mixture went bright opaque yellow to a white cloudy suspension with the evolution of gas. Upon cessation of gaseous evolution (0.5 h), the Grignard reagent was cooled to 0 °C and a solution of Weinreb amide **19** (2.09 g, 3.84 mmol) in anhydrous Et₂O (4 mL, then 2 x 2 mL) were added by cannula. The resulting dark grey suspension was stirred at 0 °C for 3 h. Saturated NH₄Cl (6 mL) was carefully added at 0 °C and the mixture allowed to warm to RT with vigorous stirring. The organic layer was separated and the aqueous phase extracted with EtOAc (4 x 30 mL). The combined organic extracts were washed with saturated NaCl (50 mL), and the aqueous washing extracted with EtOAc (30 mL). The organic extracts were dried over MgSO₄ and concentrated *in vacuo* to give a yellow oil. Purification by flash chromatography (0%, 5% EtOAc/*n*-hexane) gave the *title compound* **23** as a pale yellow oil (1.67 g, 79%). $[\alpha]_D^{20}$ -12.0 (c 1.02 in CHCl₃); R_f (5% EtOAc/*n*-hexane) 0.27; IR (film) $\nu_{\max}/\text{cm}^{-1}$ 2929 (C-H), 2857 (C-H), 1715 (C=O), 1641 (C=C), 1428, 1253, 1111, 824, 774, 701; δ_H (400 MHz, CDCl₃) -0.08 (3H, s, OSi(CH₃)₂^tBu), 0.00 (3H, s, OSi(CH₃)₂^tBu), 0.84 (9H, s, OSi(CH₃)₂^tBu), 1.04 (9H, s, OSiPh₂^tBu), 1.40–1.46 (2H, m, 8-H_A and 9-H_A), 1.55–1.72 (4H, m, 4-H, 8-H_B and 9-H_B), 2.03–2.08 (2H, m, 3-H), 2.37–2.42 (4H, m, 5-H and 7-H), 3.45 (1H, dd, ²J_{AB} 10.1 and ³J_{11A,10} 6.9, 11-H_A), 3.57 (1H, dd, ²J_{AB} 10.1 and ³J_{11B,10} 5.0, 11-H_B), 3.66–3.72 (1H, m, 10-H), 4.92–5.04 (2H, m, 1-H), 5.72–5.83 (1H, m, 2-H), 7.36–7.45 (6H, m, Ph), 7.65–7.68 (4H, m, Ph); δ_C (100 MHz, CDCl₃) -4.8 (CH₃, OSi(CH₃)₂^tBu), -4.5 (CH₃, OSi(CH₃)₂^tBu), 18.0 (C, OSi(CH₃)₂^tBu), 19.2 (C, OSiPh₂^tBu), 19.6 (CH₂, C-8), 22.8 (CH₂, C-4), 25.8 (CH₃, OSi(CH₃)₂^tBu), 26.9 (CH₃, OSiPh₂^tBu), 33.1 (CH₂, C-3), 33.9 (CH₂, C-9), 41.8 (CH₂, C-5), 43.2 (CH₂, C-7), 67.5 (CH₂, C-11), 72.5 (CH, C-10), 115.2 (CH, C-1), 127.6 (CH, Ph), 129.6 (CH, Ph), 133.6 (C, Ph), 133.6 (C, Ph), 135.6 (CH, Ph), 138.0 (CH, C-2) 210.9 (C, C-6); MS m/z (ESI+) 575 ([M + Na]⁺, 100%), 553

(M + H⁺, 12), 475 (4), 421 (15); HRMS (ESI⁺): [M + H]⁺, found 553.3535. C₃₃H₅₃O₃Si₂⁺ requires 553.3528.



(10S)-10-(tert-Butyldimethylsilyloxy)-11-(tert-butyl diphenylsilyloxy)-6-(1,3-dioxolan-2-yl)undec-1-ene (18)³


A mixture of ketone **23** (932 mg, 1.69 mmol) and ethylene glycol (190 μ L, 3.41 mmol) were azeotropically dried with toluene (3 x 1 mL). Triethyl orthoformate (820 μ L, 4.93 mmol) and Bi(OTf)₃ (39 mg, 0.059 mmol) were then added at RT. After stirring at RT for 1.75 h, the mixture turned homogeneous. Saturated NaHCO₃ (20 mL) and a few drops of aqueous NaOH (1 M) were added at RT and the aqueous phase extracted with EtOAc (3 x 20 mL). The organic extracts were washed with saturated NaCl (20 mL) and the aqueous washing extracted with EtOAc (20 mL). The combined organic extracts were dried over Na₂SO₄ and concentrated *in vacuo* to afford an opaque yellow oil. Purification by flash chromatography (0%, 5% EtOAc/*n*-hexanes) gave the *title compound* **18** as a pale yellow oil (871 mg, 86%). *R*_f (5% EtOAc/*n*-hexane) 0.27; [α]_D²³ -15.5 (c 1.08 in CHCl₃); IR (film) ν_{\max} /cm⁻¹ 2930 (C–H), 2857 (C–H), 1641 (C=C), 1428 (=C–H), 1253, 1112 (C–O–C), 824, 774, 702; δ_{H} (400 MHz, CDCl₃) -0.06 (3H, s, OSi(CH₃)₂^tBu), 0.01 (3H, s, OSi(CH₃)₂^tBu), 0.84 (9H, s, OSi(CH₃)₂^tBu), 1.05 (9H, s, OSiPh₂^tBu), 1.20–1.52 (6H, m, 4–H_A, 5–H_A, H–7_A, 8–H, and 9–H_A), 1.55–1.70 (4H, m, 4–H_B, 5–H_B, H–7_B, and 9–H_B), 2.03–2.08 (2H, m, 3–H), 3.46 (1H, dd, ²J_{AB} 10.0 and ³J_{11A,10} 6.7, 11–H_A), 3.58 (1H, dd, ²J_{AB} 10.0 and ³J_{11B,10} 5.0, 11–H_B), 3.67–3.71 (1H, m, 10–H), 3.92 (4H, s, 1'–H and 2'–H), 4.93–5.03 (2H, m, 1–H), 5.75–5.85 (1H, m, 2–H), 7.35–7.44 (6H, m, Ph), 7.66–7.69 (4H, m, Ph); δ_{C} (100 MHz, CDCl₃) -4.8 (CH₃, OSi(CH₃)₂^tBu), -4.4 (CH₃, OSi(CH₃)₂^tBu), 18.1 (C, OSi(CH₃)₂^tBu), 19.2 (C, OSiPh₂^tBu), 19.5 (CH₂, C–8), 23.1 (CH₂, C–4), 25.9 (CH₃, OSi(CH₃)₂^tBu), 26.9 (CH₃, OSiPh₂^tBu), 33.9 (CH₂, C–3), 34.7 (CH₂, C–9), 36.7 (CH₂, C–5), 37.5 (CH₂, C–7), 64.9 (2 x CH₂, C–1' and C–2'), 67.8 (CH₂, C–11), 72.9 (CH, C–10), 111.7 (C, C–6), 114.6 (CH₂, C–1) 127.6 (CH, Ph), 129.6 (CH, Ph), 133.7 (C, Ph), 133.7 (C, Ph), 135.6 (CH, Ph), 138.7 (CH, C–2); MS *m/z* (ESI⁺, MS₂⁺ (597)) 597 (17%), 519 ([M – Ph]⁺, 23), 465 ([M – OTDBMS]⁺, 69), 403 (36), 383 (100), 329 (57), 279 (21); HRMS (ESI⁺): [M + H]⁺, found 597.3791. C₃₅H₅₇O₄Si₂ requires 597.3790.



(9S)-9-(tert-Butyl-dimethylsilyloxy)-10-(tert-butyl diphenylsilyloxy)-5-(1,3-dioxolan-2-yl) decanal (24)⁴


To a solution of acetal **18** (738 mg, 1.24 mmol) in anhydrous CH₂Cl₂ (46 mL) was added a few drops of Sudan III indicator (0.1% in CH₂Cl₂). The bright red solution was cooled to -78 °C and O₃ was bubbled through the solution for 1 h (O₃ generator settings, flow rate: 50 L/h, discharge: 100 V,

O₂ pressure: 15 psi) until complete discoloration was observed. While maintaining the reaction mixture at -78 °C, the reaction vessel was flushed with nitrogen for 0.5 h whereupon the reaction mixture turned pale orange. NEt₃ (860 μL, 1.65 mmol) was slowly added at -78 °C, stirred for 5 mins, then warmed to RT. The organic phase was dried over Na₂SO₄, passed through a glass sinter and the filtrate concentrated *in vacuo* to obtain pale red oil. Purification by flash chromatography (0%, 20% EtOAc/*n*-hexane) afforded the *title compound* **24** as a yellow oil (518 mg, 69%). [α]_D²² -13.5 (c 1.04 in CHCl₃); *R_f* (20% EtOAc/*n*-hexane) 0.33, (33% EtOAc/*n*-hexane) 0.55; IR (film) ν_{\max} /cm⁻¹ 2929 (C–H), 2857 (C–H), 1726 (C=O), 1428 (C–H), 1389, 1111 (C–O–C), 701; δ_{H} (300 MHz, CDCl₃) -0.06 (3H, s, OSi(CH₃)₂^tBu), 0.01 (3H, s, OSi(CH₃)₂^tBu), 0.84 (9H, s, OSi(CH₃)₂^tBu), 1.05 (9H, s, OSiPh₂^tBu), 1.32–1.55 (3H, m, 7–H, and 8–H_A), 1.58–1.75 (7H, m, 3–H, 4–H, 6–H, and 8–H_B), 2.44 (2H, td, *J*_{2,1} 1.7 and *J*_{2,3} 7.2, 2–H), 3.46 (1H, dd, ²*J*_{AB} 10.0 and ³*J*_{10A,9} 6.7, 10–H_A), 3.58 (1H, dd, ²*J*_{AB} 10.0 and ³*J*_{10B,9} 5.0, 10–H_B), 3.66–3.71 (1H, m, 9–H), 3.92 (4H, s, 1'–H and 2'–H), 7.34–7.45 (6H, m, Ph), 7.65–7.70 (4H, m, Ph), 9.76 (1H, t, *J*_{1,2} 1.7, 1–H); δ_{C} (75 MHz, CDCl₃) -4.8 (CH₃, OSi(CH₃)₂^tBu), -4.4 (CH₃, OSi(CH₃)₂^tBu), 16.5 (CH₂, C–3), 18.1 (C, OSi(CH₃)₂^tBu), 19.2 (C, OSiPh₂^tBu), 19.5 (CH₂, C–7), 25.8 (CH₃, OSi(CH₃)₂^tBu), 26.9 (CH₃, OSiPh₂^tBu), 34.7 (CH₂, C–8), 36.4 (CH₂, C–4), 37.5 (CH₂, C–6), 43.9 (CH₂, C–2), 65.0 (2 x CH₂, C–1' and C–2'), 67.8 (CH₂, C–10), 72.8 (CH, C–9), 111.3 (C, C–5), 127.6 (CH, Ph), 129.6 (CH, Ph), 129.6 (CH, Ph), 133.7 (C, Ph), 133.7 (C, Ph), 135.6 (CH, Ph), 135.6 (CH, Ph), 202.3 (CH, C–1); MS *m/z* (ESI⁺) 669 (19%), 653 (100), 637 ([M + K]⁺, 26), 621 ([M + Na]⁺, 68), 599 ([M + H]⁺, 4), (7); HRMS (ESI⁺): [M + H]⁺, found 599.3583. C₃₄H₅₅O₅Si₂⁺ requires 599.3583.




(3*S*,11*S*)- and (3*R*,11*S*)-11-(*tert*-Butyldimethylsilyloxy)-12-(*tert*-butyldiphenylsilyloxy)-7-(1,3-dioxolan-2-yl)dodec-1-yn-(3)-ol (17a:17b)

To a solution of aldehyde **24** (1.27 g, 2.12 mmol) in anhydrous THF (20 mL) at 0 °C under an argon atmosphere was added a solution of ethynylmagnesium bromide (0.5 M in THF, 34 mL, 17 mmol). After stirring at 0 °C for 3 h, saturated NH₄Cl (10 mL) and distilled H₂O (5 mL) were added and the mixture stirred vigorously. The phases were separated and the aqueous phase extracted with EtOAc (3 x 20 mL). The organic extracts were washed with saturated NaCl (50 mL) and the aqueous washing extracted with EtOAc (40 mL). The combined organic extracts were then dried over Na₂SO₄ and the solvent removed *in vacuo*. The resulting dark brown oil was purified by flash chromatography (0%, 20% to 33% EtOAc/*n*-hexane) to afford an inseparable diastereomeric mixture of the *title compound* **17a:17b** as a thick golden oil (963 mg, 73%). The characterisation data of compound **17** is provided in the procedure describing the hydrolysis of acetate **25** to alkynol **17a**.



(11S)-11-(tert-Butyldimethylsilyloxy)-12-(tert-butyl(diphenyl)silyloxy)-7-(1,3-dioxolan-2-yl)dodec-1-yn-3-one (26)


IBX (87.3 mg, 0.312 mmol) was dissolved in DMSO (600 μ L) and stirred at RT for 15 mins. A solution of alkynol **17a:17b** (83 mg, 0.133 mmol) in anhydrous DMSO (3 x 900 μ L) was added and the reaction mixture heated to 40 °C. After 2.5 h, the reaction mixture was allowed to cool to RT and saturated $\text{Na}_2\text{S}_2\text{O}_3$ (3 mL) and EtOAc (3 mL) were added. The aqueous phase was extracted with EtOAc (4 x 15 mL) and the organic extracts washed with saturated NaCl (50 mL). The aqueous washing was back extracted with EtOAc (50 mL) and the combined organic extracts dried over Na_2SO_4 and the EtOAc removed *in vacuo* to give an orange solution. Purification by flash chromatography (0%, 17% EtOAc/*n*-hexane) afforded the *title compound* **26** as a pale yellow oil (80 mg, 96%). $[\alpha]_D^{22}$ -11.8 (c 1.07 in CHCl_3); R_f (17% EtOAc/*n*-hexane) 0.30; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 3309 ($\equiv\text{C-H}$), 2929 (C-H), 2858 (C-H), 2091 (C \equiv C), 1734 (C=O), 1683, 1472, 1187, 1106 (C-O-C), 835, 701; δ_{H} (400 MHz, CDCl_3) -0.07 (3H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 0.00 (3H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 0.84 (9H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 1.04 (9H, s, $\text{OSiPh}_2^t\text{Bu}$), 1.29–1.52 (4H, m, 8-H, 9- H_A and 10- H_A), 1.54–1.69 (4H, m, 6-H, 9- H_B , and 10- H_B), 1.72–1.80 (2H, m, 5-H), 2.60 (2H, t, $^3J_{4,5}$ 7.3, 4-H), 3.18 (1H, s, 1-H), 3.46 (1H, dd, $^2J_{AB}$ 10.0 and $^3J_{12A,11}$ 6.7, 12- H_A), 3.57 (1H, dd, $^2J_{AB}$ 10.0 and $^3J_{12B,11}$ 5.0, 12- H_B), 3.66–3.72 (1H, m, 11-H), 3.92 (4H, s, 1'-H and 2'-H), 7.35–7.44 (6H, m, Ph), 7.65–7.69 (4H, m, Ph); δ_{C} (100 MHz, CDCl_3) -4.8 (CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), -4.4 (CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 18.1 (C, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 18.1 (CH_2 , C-5), 19.2 (C, $\text{OSiPh}_2^t\text{Bu}$), 19.4 (CH_2 , C-9), 25.9 (CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 26.9 (CH_3 , $\text{OSiPh}_2^t\text{Bu}$), 34.7 (CH_2 , C-8), 36.1 (CH_2 , C-10), 37.5 (CH_2 , C-6), 45.4 (CH_2 , C-4), 65.0 (2 x CH_2 , C-1' and C-2'), 67.8 (CH_2 , C-12), 72.8 (CH, C-11), 78.3 (CH, C-1), 81.4 (C, C-2) 111.3 (C, C-7), 127.6 (CH, Ph), 129.6 (CH, Ph), 133.7 (C, Ph), 133.7 (C, Ph), 135.6 (CH, Ph), 187.1 (C, C-3); MS m/z (ESI+) 661 ($[\text{M} + \text{K}]^+$, 6%), 645 ($[\text{M} + \text{Na}]^+$, 24), 640 ($[\text{M} + \text{H}_2\text{O}]^+$, 100), 623 ($[\text{M} + \text{H}]^+$, 14), 605 (30), 545 (15), 527 (7), 491 (16); HRMS (ESI+): $[\text{M} + \text{H}]^+$, found 623.3571. $\text{C}_{36}\text{H}_{55}\text{O}_5\text{Si}_2^+$ requires 623.3583.



(3S,11S)-11-(tert-Butyldimethylsilyloxy)-12-(tert-butyl(diphenyl)silyloxy)-7-(1,3-dioxolan-2-yl)dodec-1-yn-3-yl acetate (25)


To a solution of alkynol **17a:17b** (1.12 g, 1.79 mmol) in distilled hexanes (48 mL) in a 80 mL microwave reaction tube, was added vinyl acetate (300 μ L, 3.25 mmol) and Novozyme 435 lipase acrylic resin (252 mg, derived from *Candida antarctica*, 141 mg/mmol). The mixture was heated in a microwave reactor (CEM Discover, 50W) to a maximum of 50 °C for 1 h. The reaction mixture was filtered through a glass sinter, washed with EtOAc (20 mL) and concentrated *in vacuo* to get a pale yellow oil. Purification by flash chromatography (0%, 14% to 25% EtOAc/*n*-hexane) gave the *title compound* **25** as a pale yellow oil (214 mg, 18%) and alkynols **17a:17b** as a yellow oil (799 mg,

72%). The alkynol fractions were concentrated and resubjected to the enzymatic kinetic resolution as described above to afford a second portion of the *title compound 25* as a pale yellow oil (155 mg, 13%) and alkynols **17a:17b** (617 mg, 55%). $[\alpha]_D^{20}$ -28.4 (c 1.07 in CHCl_3); R_f (17% EtOAc/*n*-hexane) 0.35; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 3293 ($\equiv\text{C-H}$), 2956 (C-H), 2859 (C-H), 1744 (C=O), 1473, 1429, 1372 ($\equiv\text{C-H}$), 1233 (C-C(=O)-O), 1112 (C-O-C), 703; δ_{H} (400 MHz, CDCl_3) -0.07 (3H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 0.00 (3H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 0.84 (9H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 1.04 (9H, s, $\text{OSiPh}_2^t\text{Bu}$), 1.30–1.69 (10H, m, 5-H, 6-H, 8-H, 9-H and 10-H), 1.75–1.80 (2H, m, 4-H), 2.08 (3H, s, COCH_3), 2.44 (1H, d, $^4J_{1,3}$ 2.0, 1-H), 3.46 (1H, dd, $^2J_{\text{AB}}$ 10.0 and $^3J_{12\text{A},11}$ 6.5, 12-H_A), 3.57 (1H, dd, $^2J_{\text{AB}}$ 10.0 and $^3J_{12\text{B},11}$ 5.0, 12-H_B), 3.66–3.70 (1H, m, 11-H), 3.90–3.94 (4H, m, 1'-H and 2'-H), 5.34 (1H, td, $^3J_{3,4}$ 6.5 and $^4J_{3,1}$ 2.0, 3-H), 7.35–7.44 (6H, m, Ph), 7.65–7.68 (4H, m, Ph); δ_{C} (100 MHz, CDCl_3) -4.8 (CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), -4.4 (CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 18.1 (C, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 19.2 (C, $\text{OSiPh}_2^t\text{Bu}$), 19.3 (CH_2 , C-5), 19.5 (CH_2 , C-9), 21.0 (CH_3 , COCH_3), 25.8 (CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 26.8 (CH_3 , $\text{OSiPh}_2^t\text{Bu}$), 34.7 (2 x CH_2 , C-4 and C-10), 36.7 (CH_2 , C-6), 37.5 (CH_2 , C-8), 63.7 (CH_2 , C-3), 65.0 (2 x CH_2 , C-1' and C-2'), 67.8 (CH_2 , C-12), 72.8 (CH, C-11), 73.6 (CH, C-1), 81.1 (C, C-2) 111.4 (C, C-7), 127.6 (CH, Ph), 129.6 (CH, Ph), 133.6 (C, Ph), 133.7 (C, Ph), 135.6 (CH, Ph), 169.9 (C, COCH_3); MS m/z (ESI+) 705 ($[\text{M} + \text{K}]^+$, 7%), 689 ($[\text{M} + \text{Na}]^+$, 100), 684 ($[\text{M} + \text{H}_2\text{O}]^+$, 26), 667 ($[\text{M} + \text{H}]^+$, 6), 645 (25), 589 (13), 535 (7); HRMS (ESI+): $[\text{M} + \text{H}]^+$, found 667.3846. $\text{C}_{38}\text{H}_{59}\text{O}_6\text{Si}_2^+$ requires 667.3845.




Hydrolysis of (3*S*,11*S*)-11-(*tert*-Butyldimethylsilyloxy)-12-(*tert*-butyldiphenylsilyloxy)-7-(1,3-dioxolan-2-yl)dodec-1-yn-3-yl acetate (**25**) to (3*S*,11*S*)-11-(*tert*-butyldimethylsilyloxy)-12-(*tert*-butyldiphenylsilyloxy)-7-(1,3-dioxolan-2-yl)dodec-1-yn-3-ol (**17a**)


To a solution of acetate **25** (369 mg, 0.553 mmol) in CH_3OH (11 mL) at RT was added solid K_2CO_3 (160 mg, 1.16 mmol). After stirring for 20 mins the mixture was filtered and washed with EtOAc (20 mL) and the filtrate concentrated *in vacuo* to afford a thick yellow oil. Purification by flash chromatography (0%, 20% to 25% EtOAc/*n*-hexanes) gave (3*S*,11*S*)-alkynol **17a** as a colourless oil (337 mg, 97%, 90–96% d.e.).⁵ $[\alpha]_D^{21}$ -14.0 (c 1.03 in CHCl_3); R_f (20% EtOAc/*n*-hexane) 0.11, R_f (50% EtOAc/*n*-hexane) 0.58; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 3411 (br, O-H), 3309 ($\equiv\text{C-H}$), 2929 (C-H), 2857 (C-H), 1472, 1428 (C-H), 1253, 1111 (C-O-C), 824, 775, 701; δ_{H} (400 MHz, CDCl_3) -0.06 (3H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 0.00 (3H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 0.84 (9H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 1.05 (9H, s, $\text{OSiPh}_2^t\text{Bu}$), 1.33–1.49 (3H, m, 5-H_A, 9-H_A and 10-H_A), 1.51–1.87 (9H, m, 4-H, 5-H_B, 6-H, 8-H, 9-H_B and 10-H_B), 2.45 (1H, d, $^4J_{1,3}$ 2.0, 1-H), 3.46 (1H, dd, $^2J_{\text{AB}}$ 10.0 and $^3J_{12\text{A},11}$ 6.6, 12-H_A), 3.58 (1H, dd, $^2J_{\text{AB}}$ 10.0 and $^3J_{12\text{B},11}$ 5.0, 12-H_B), 3.66–3.73 (1H, m, 11-H), 3.90–3.95 (4H, m, 1'-H and 2'-H), 4.33–4.39 (1H, m, 3-H), 7.35–7.45 (6H, m, Ph), 7.66–7.68 (4H, m, Ph); δ_{C} (100 MHz, CDCl_3) -4.8 (CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), -4.4 (CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 18.1 (C, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 19.2 (C, $\text{OSiPh}_2^t\text{Bu}$), 19.4 (CH_2 , C-5), 19.5 (CH_2 , C-9), 25.8 (CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 26.8 (CH_3 , $\text{OSiPh}_2^t\text{Bu}$), 34.7 (CH_2 , C-10), 36.7 (CH_2 , C-6), 37.5 (CH_2 , C-8), 37.8 (CH_2 , C-4) 62.2 (CH, C-3), 65.0 (2 x CH_2 , C-1' and C-2'), 67.8 (CH_2 , C-12), 72.8 (CH, C-11), 72.9 (CH, C-1), 84.9 (C, C-2) 111.6 (C, C-7), 127.6 (CH, Ph), 129.6 (CH, Ph), 129.6 (CH, Ph), 133.7 (C, Ph), 133.7 (C, Ph), 135.6 (CH, Ph); MS m/z (ESI+) 647 ($[\text{M} + \text{Na}]^+$, 48%), 563 (100), 431 (4), 307 (10); HRMS (ESI+): $[\text{M} + \text{Na}]^+$, found 647.3574. $\text{C}_{36}\text{H}_{56}\text{NaO}_5\text{Si}_2^+$ requires 647.3558.





8-Ethynyl-2-(tert-butyldiphenylsilyloxymethyl)-1,7-dioxaspiro[5.5]undecane (**11**)


To a stirred solution of alkynol **17a** (337 mg, 0.539 mmol) in EtOH:H₂O (99:1 mixture, 5.8 mL) was added (+)-CSA (272 mg, 1.17 mmol) in three equal portions at RT. After stirring for 3 h, solid NaHCO₃ (104 mg, 0.33 mmol) was added directly and the solvent was removed *in vacuo* to afford a yellow oil. The yellow oil was dissolved in saturated NaHCO₃ (10 mL) and the aqueous phase extracted with EtOAc (3 x 20 mL). The combined organic extracts were dried over MgSO₄ and concentrated *in vacuo* to afford an orange oil. Purification by flash chromatography (0%, 9% EtOAc/*n*-hexane) gave the *title compound* **11** as a yellow oil (181 mg, 75%). $[\alpha]_D^{21}$ -9.3 (c 1.05 in CHCl₃); R_f (9% EtOAc/*n*-hexane) 0.30; IR (film) $\nu_{\max}/\text{cm}^{-1}$ 3292 ($\equiv\text{C-H}$), 2932 (C-H), 2858 (C-H), 1473 (CH₂), 1428 (C-H), 1219, 1112 (C-O-C), 1072 (C-O-C), 980; δ_{H} (300 MHz, CDCl₃) 1.06 (9H, s, OSiPh₂^tBu), 1.14–1.28 (1H, m, 3-H_A), 1.34–1.64 (6H, m, 3-H_B, 4-H, 5-H_A, 9-H_A, and 10-H_A), 1.66–1.81 (3H, m, 9-H_B and 11-H), 1.88–2.03 (2H, m, 5-H_B and 10-H_B), 2.43 (1H, d, $^4J_{2,8}$ 2.3, 2'-H), 3.58 (1H, dd, $^3J_{\text{AB}}$ 10.3 and $^3J_{2-\text{CH}_2,2}$ 4.4, 2-CH_AH_BO), 3.68 (1H, dd, $^3J_{\text{AB}}$ 10.3 and $^3J_{2-\text{CH}_2,2}$ 6.5, 2-CH_AH_BO), 3.77–3.87 (1H, m, 2-H), 4.53 (1H, dt, $^3J_{8,9\text{ax}}$ 11.4, $^3J_{8,9\text{eq}}$ 2.6, and $^4J_{8,2'}$ 2.3, 8-H), 7.35–7.45 (6H, m, Ph), 7.68–7.76 (4H, m, Ph); δ_{C} (75 MHz, CDCl₃) 18.35, 18.4 (2 x CH₂, C-4 and C-10), 19.2 (C, OSiPh₂^tBu), 26.75 (CH₃, OSiPh₂^tBu), 26.8 (CH₂, C-3), 31.8 (CH₂, C-9), 34.7, 35.0 (2 x CH₂, C-5 and C-11), 59.8 (CH, C-8), 67.3 (CH₂, 2-CH₂O), 70.6 (CH, C-2), 71.7 (CH, C-2'), 84.1 (C, C-1'), 96.6 (C, C-6), 127.6 (CH, Ph), 127.6 (CH, Ph), 129.5 (CH, Ph), 129.6 (CH, Ph), 133.8 (C, Ph), 135.7 (C, Ph); MS m/z (ESI+) 487 ([M + K]⁺, 100%), 471 ([M + Na]⁺, 11), 429 (22), 371 ([M - Ph]⁺, 12); HRMS (ESI+): [M + K]⁺, found 487.2084. C₂₈H₃₆KO₃Si⁺ requires 487.2065.








































Experimental and Characterization data for azides **27a-h** and intermediates involved in the synthesis of **27a-h**.




1-Azidooctane (**27a**)

To a solution of 1-bromooctane (60 μ L, 0.347 mmol) in anhydrous DMF (2 mL) was added NaN_3 (62 mg, 0.95 mmol). The reaction mixture was heated to 80 $^\circ\text{C}$ for 21 h. Upon cooling to RT, H_2O (5 mL) was added and the aqueous phase extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried over MgSO_4 and concentrated *in vacuo* to get a yellow oil. Purification by flash chromatography (0%, 0.5% $\text{Et}_2\text{O}/n$ -hexane) afforded the *title compound* **27a** as a colourless oil (53 mg, 98%). R_f (0.5% $\text{Et}_2\text{O}/n$ -hexanes) 0.40; δ_{H} (400 MHz, CDCl_3) 0.89 (3H, t, $^3J_{8,7}$ 7.0, 8-H), 1.28–1.38 (10H, m, 3-H, 4-H, 5-H, 6-H and 7-H), 1.56–1.63 (2H, m, 2-H), 3.25 (2H, t, $^3J_{1,2}$ 6.8, 1-H); δ_{C} (100 MHz, CDCl_3) 14.0 (CH_3 , C-8), 22.6 (CH_2 , C-7), 26.7 (CH_2 , C-3), 28.8 (CH_2 , C-4), 29.1, 29.1 (2 x CH_2 , C-2 and C-5), 31.7 (CH_2 , C-6), 51.5 (CH_2 , C-1). ^1H and ^{13}C NMR spectra were in agreement with that from literature sources.⁶




14-Azidotetradecane-2,5-dione (**27b**)

To a stirred solution of the corresponding tosylate (70.0 mg, 0.177 mmol) dissolved in DMF (5.0 mL) was added NaN_3 (13.0 mg, 0.2 mmol) and the yellow solution was left to stir at RT for 4 h. Addition NaN_3 (35.0 mg, 0.53 mmol) was added and the reaction mixture was left to stir at RT for a further 20 h. The mixture was then diluted with EtOAc (5 mL) and filtered through a silica plug that was washed with EtOAc (50 mL). Concentration of the filtrate *in vacuo* gave an orange oil that was purified by flash chromatography (0%, 25% to 33% EtOAc/*n*-hexane) to afford the *title compound* **27b** as a colourless solid (44.1 mg, 93%). Mp. 24–26 $^\circ\text{C}$; R_f (25% EtOAc/*n*-hexane) 0.29, (33% EtOAc/*n*-hexane) 0.52; δ_{H} NMR (300 MHz, CDCl_3) 1.27–1.38 (10H, m, 8-H, 9-H, 10-H, 11-H and H-12), 1.54–1.62 (4H, m, 7-H and 13-H), 2.19 (3H, s, 1-H), 2.44 (2H, t, $^3J_{6,7}$ 7.5, 6-H), 2.65–2.72 (4H, m, 3-H and 4-H), 3.25 (2H, t, $^3J_{14,13}$ 6.0, 14-H); δ_{C} NMR (100 MHz, CDCl_3) 23.8 (CH_2 , C-7), 26.7 (CH_2 , C-12), 28.8, 29.05, 29.1, 29.2, 29.2 (5 x CH_2 , C-8, C-9, C-10, C-11 and C-13), 30.0 (CH_3 , C-1), 36.0 (CH_2 , C-3), 36.9 (CH_2 , C-4), 42.8 (CH_2 , C-6), 51.5 (CH_2 , C-14), 207.3 (C, C-2), 209.6 (C, C-5). The ^1H and ^{13}C NMR spectroscopic data obtained were in agreement with literature values.⁷




11-Bromoundecan-2-one⁸

A 2-necked round bottom flask flushed with argon was charged with CuCl (73 mg, 0.74 mmol), PdCl₂ (62 mg, 0.35 mmol), and 11-bromoundecene (159 mg, 0.68 mmol). The reagents were suspended in a mixture of DMF and distilled H₂O (3:1, 4 mL) and cooled to 0 °C. *tert*-Butylhydroperoxide (5.5M in decane, 140 μL, 0.77 mmol), was then added dropwise and the stirred reaction mixture allowed to warm to RT. After 20 h, saturated Na₂SO₃ (2 mL) was added and after vigorous stirring, the black mixture was washed through a silica plug with EtOAc (100 mL) and the filtrate concentrated *in vacuo* to afford an orange oil. Purification by flash chromatography (0%, 9% EtOAc/*n*-hexane) yielded the *title compound* as a pale orange oil (144 mg, 67%). *R_f* (9% EtOAc/*n*-hexane) 0.25; IR (film) $\nu_{\max}/\text{cm}^{-1}$ 2926 (C–H), 2854 (C–H), 1715 (C=O), 1464, 1357, 1164, 720, 643 (C–Br); δ_{H} (400 MHz, CDCl₃) 1.12–1.18 (8H, m, 5–H, 6–H, 7–H, and 8–H), 1.26–1.30 (2H, m, 9–H), 1.42 (2H, m, 4–H), 1.71 (2H, m, 10–H), 1.99 (3H, s, 1–H), 2.28 (2H, t, ³*J*_{3,4} 7.4, 3–H), 3.26 (2H, t, ³*J*_{11,10} 6.9, 11–H); δ_{C} (100 MHz, CDCl₃) 23.4 (CH₂, C–4), 27.8 (CH₂, C–9), 28.3, 28.7, 28.9, 28.9 (4 x CH₂, C–5, C–6, C–7, and C–8), 29.5 (CH₃, C–1), 32.4 (CH₂, C–10), 35.6 (CH₂, C–11), 43.3 (CH₂, C–3), 208.5 (C, C–2); MS *m/z* (ESI⁺) 271 ([M + Na]⁺, Br isotope, 100%), 251 ([M + H]⁺, Br isotope, 19), 191 ([M – C₃H₅O]⁺, 36); HRMS (ESI⁺): [M + Na]⁺, found 271.0671. C₁₁H₂₁BrNaO requires 271.0668.




11-Azidoundecan-2-one (27c)

To a solution of 11-bromoundecan-2-one (84.3 mg, 0.34 mmol) in anhydrous DMF (6.5 mL) was added NaN₃ (45 mg, 0.69 mmol). The colourless mixture was stirred at RT for 17 h whereupon the reaction mixture had turned a pale yellow colour. EtOAc (5 mL) was added and the reaction mixture passed through a silica plug with EtOAc (100 mL). The filtrate was concentrated *in vacuo* to give an orange oil that was purified by flash chromatography (0%, 9% EtOAc/*n*-hexane) to yield the *title compound* 27c as a pale yellow oil (52 mg, 72%). *R_f* (9% EtOAc/*n*-hexane) 0.24; IR (film) $\nu_{\max}/\text{cm}^{-1}$ 2927 (C–H), 2855 (C–H), 2092 (C–N=N⁺=N⁻), 1715 (C=O), 1457, 1355, 1256, 1164, 720; δ_{H} (400 MHz, CDCl₃) 1.25–1.34 (10H, m, 5–H, 6–H, 7–H, 8–H, and 9–H), 1.51–1.59 (4H, m, 4–H and 10–H), 2.10 (3H, s, 1–H), 2.38 (2H, t, ³*J*_{3,4} 7.4, 3–H), 3.22 (2H, t, ³*J*_{11,10} 6.9, 11–H); δ_{C} (100 MHz, CDCl₃) 23.7 (CH₂, C–4), 26.6 (CH₂, C–9), 28.7 (CH₂, C–10), 29.0, 29.0, 29.2 (4 x CH₂, C–5, C–6, C–7, and C–8), 29.7 (CH₃, C–1), 43.6 (CH₂, C–3), 51.4 (CH₂, C–11), 209.1 (C, C–2); MS *m/z* (ESI⁺) 234 ([M + Na]⁺, 100%), 184 ([M + H – N₂]⁺, 7); HRMS (ESI⁺): [M + Na]⁺, found 234.1582. C₁₁H₂₁N₃NaO requires 234.1577.




10-(*tert*-Butyldimethylsilyloxy)decyl-4-methylbenzenesulfonate

To a solution of mono-TBMDS protected decanol (150.0 mg, 0.52 mmol) in anhydrous CH_2Cl_2 (1.3 mL) was added NEt_3 (220 μL , 1.56 mmol), DMAP (32.5 mg, 0.27 mmol) and 4-toluenesulfonyl chloride (186.6 mg, 0.98 mmol). The mixture was stirred at RT for 18 h and then passed through a plug of celite with EtOAc (50 mL). The filtrate was concentrated *in vacuo* to get an orange residue. Purification by flash chromatography (0%, 5% to 17% EtOAc/*n*-hexane) gave the *title compound* as a yellow oil (195.4 mg, 85%). R_f (5% EtOAc/*n*-hexane) 0.24; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 2928 (C–H), 2856 (C–H), 1362 (S=O), 1189 (S=O), 1177 (S=O), 1098 (C–O), 834; δ_{H} (400 MHz, CDCl_3) 0.04 (6H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 0.89 (9H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 1.22–1.28 (12H, m, 3'–H, 4'–H, 5'–H, 6'–H, 7'–H and 8'–H), 1.47–1.51 (2H, m, 2'–H), 1.59–1.64 (2H, m, 9'–H), 2.45 (3H, s, PhCH_3), 3.59 (2H, t, $^3J_{1,2}$ 6.6, 1'–H), 4.01 (2H, t, $^3J_{10,9'}$ 6.6, 10'–H), 7.34 (2H, d, $^3J_{2,3}$ and $^3J_{5,6}$ 8.2, 2–H and 6–H), 7.79 (2H, d, $^3J_{3,2}$ and $^3J_{5,6}$ 8.2, 3–H and 5–H); δ_{C} (100 MHz, CDCl_3) –5.3 (2 x CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 18.4 (C, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 21.6 (CH_3 , PhCH_3), 25.3 (CH_2 , C–3'), 25.8 (CH_2 , C–8'), 26.0 (CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 28.8 (CH_2 , C–7'), 28.9 (CH_2 , C–9'), 29.3, 29.4, 29.4 (3 x CH_2 , C–4', C–5' and C–6'), 32.8 (CH_2 , C–2'), 63.3 (CH_2 , C–1'), 70.7 (CH_2 , C–10'), 127.9 (2 x CH, C–2 and C–6), 129.8 (2 x CH, C–3 and C–5), 133.2 (C, C–1), 144.6 (C, C–4); MS m/z (ESI+) 907 ($[\text{M}_2 + \text{Na}]^+$, 3%), 465 ($[\text{M} + \text{Na}]^+$, 100), 443 ($[\text{M} + \text{H}]^+$, 70), 351 ($[\text{M} - \text{PhCH}_3]^+$, 3), 287 ($[\text{M} - \text{S}(\text{O})_2\text{PhCH}_3]^+$, 68); HRMS (ESI+): $[\text{M} + \text{H}]^+$, found 443.2650. $\text{C}_{23}\text{H}_{43}\text{O}_4\text{SSi}$ requires 443.2646.




10-(Azidodecyloxy)-1-*tert*-butyldimethylsilane (27d)

To a solution of 10-(*tert*-butyldimethylsilyloxy)decyl 4-methylbenzenesulfonate (52 mg, 0.12 mmol) in anhydrous DMF (390 μL) was added NaN_3 (26.7 mg, 0.41 mmol) at RT. After stirring at RT for 17 h, the reaction mixture was passed through a plug of silica and washed through with EtOAc (40 mL). The filtrate was concentrated *in vacuo* to get an orange oil. Purification by flash chromatography (0%, 2.5% EtOAc/*n*-hexane) gave the *title compound 27d* as a pale yellow oil (32.3 mg, 88%). R_f (2.5% EtOAc/*n*-hexane) 0.29; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 2928 (C–H), 2856 (C–H), 2095 (C–N=N⁺=N⁻), 1471, 1361, 1256, 1098 (C–O), 835, 775; δ_{H} (300 MHz, CDCl_3) 0.04 (6H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 0.89 (9H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 1.28–1.45 (12H, m, 3–H, 4–H, 5–H, 6–H, 7–H and 8–H), 1.48–1.55 (2H, m, 2–H), 1.57–1.62 (2H, m, 9–H), 3.25 (2H, t, $^3J_{10,9}$ 6.9, 10–H), 3.59 (2H, t, $^3J_{1,2}$ 6.6, 1–H); δ_{C} (75 MHz, CDCl_3) –5.3 (2 x CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 18.4 (C, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 25.8 (CH_2 , C–3), 26.0 (CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 26.7 (CH_2 , C–8), 28.8 (CH_2 , C–7), 29.1 (CH_2 , C–9), 29.4, 29.4, 29.5 (3 x CH_2 , C–4, C–5 and C–6), 32.8 (CH_2 , C–2), 51.5 (CH_2 , C–10), 63.3 (CH_2 , C–1); MS m/z (ESI+) 336 ($[\text{M} + \text{Na}]^+$, 29%), 314 ($[\text{M} + \text{H}]^+$, 63), 286 ($[\text{M} + \text{H} - \text{N}_2]^+$, 69), 270 ($[\text{M} - \text{HN}_3]^+$, 11), 154 ($[\text{M} - \text{CH}_2\text{CH}_2\text{OTBDMS}]^+$, 100), 133 (24); HRMS (ESI+): $[\text{M} + \text{H}]^+$, found 314.2624. $\text{C}_{16}\text{H}_{36}\text{N}_3\text{OSi}$ requires 314.2622.




Methyl 6-bromohexanoate

DMAP (40 mg, 0.328 mmol) and EDCI•HCl (436 mg, 2.27 mmol) were added to a solution of 6-bromohexanoic acid (300 mg, 1.538 mmol) in CH₃OH (320 μL, 12.6 mmol) at RT. After stirring for 5 h, the reaction mixture was quenched with H₂O (5 mL) and the organic phase separated. The aqueous phase was extracted with EtOAc (2 x 10 mL) and the combined organic extracts washed with saturated NaCl (20 mL). The aqueous washing was extracted with EtOAc (20 mL) and the organic extracts dried over MgSO₄ and then concentrated *in vacuo* to get a yellow oil. Purification by flash chromatography (0%, 14% EtOAc/*n*-hexane) gave *methyl 6-bromohexanoate* as a pale yellow liquid (261 mg, 81%). *R_f* (14% EtOAc/*n*-hexane) 0.27; δ_H (400 MHz, CDCl₃) 1.43–1.51 (2H, m, 4–H), 1.61–1.69 (2H, m, 3–H), 1.83–1.91 (2H, m, 5–H) 2.33 (2H, t, ³*J*_{2,3} 7.4, 2–H), 3.40 (2H, t, ³*J*_{6,5} 6.8 Hz, 6–H), 3.67 (3H, s, OCH₃); δ_C (100 MHz, CDCl₃) 24.0 (CH₂, C–3), 27.6 (CH₂, C–4), 32.3 (CH₂, C–5), 33.5 (CH₂, C–2), 33.8 (CH₂, C–6), 51.5 (CH₃, OCH₃), 173.9 (C, C–1). The ¹H and ¹³C NMR spectra obtained was in agreement with that reported in the literature.⁹




Methyl 6-azidohexanoate (27e)

NaN₃ (65 mg, 1.00 mmol) and TBAI (199 mg, 0.59 mmol) were added to a solution of methyl 6-bromohexanoate (56 mg, 0.27 mmol) in DMF (900 μL) at RT. The red mixture was heated to 70 °C for 20.5 h where the mixture went colourless. After cooling to RT, H₂O (2 mL) and EtOAc (2 mL) were added and the organic phase separated. The aqueous phase was extracted with EtOAc (3 x 10 mL) and the combined organic extracts dried over MgSO₄. Concentration of the organic extracts *in vacuo* gave a pale red oil that was purified by flash chromatography (0%, 14% EtOAc/*n*-hexane) to afford the *title compound 27e* as a pale yellow oil (41 mg, 89%). *R_f* (14% EtOAc/*n*-hexane) 0.28; δ_H (300 MHz, CDCl₃) 1.35–1.46 (2H, m, 4–H), 1.57–1.71 (4H, m, 3–H and 5–H), 2.33 (2H, t, ³*J*_{2,3} 7.4, 2–H), 3.27 (2H, t, ³*J*_{6,5} 6.8 Hz, 6–H), 3.67 (3H, s, OCH₃); δ_C (75 MHz, CDCl₃) 24.4 (CH₂, C–3), 26.2 (CH₂, C–4), 28.5 (CH₂, C–5), 33.8 (CH₂, C–2), 51.2 (CH₂, C–6), 51.5 (CH₃, OCH₃), 173.9 (C, C–1). The ¹H and ¹³C NMR spectra obtained was in agreement with that reported in the literature.⁹




1-(4-Azidophenyl)ethanone (27f)

To a suspension of 4-amino-acetophenone (150 mg, 1.11 mmol) in H₂O (2.2 mL) at 0 °C, was added concentrated HCl (12 M, 240 μL). A solution of NaNO₂ (86.0 mg, 1.25 mmol) in H₂O (2.8 mL) was added dropwise at a rate to maintain a reaction temperature < 5 °C, whereupon completion of addition, the off-white suspension had dissolved to a bright yellow solution. The reaction was stirred at 0 °C for 0.5 h, and then NaN₃ (88.9 mg, 1.37 mmol) was added slowly to maintain a reaction temperature of < 5 °C. The reaction mixture was wrapped in aluminium foil and allowed to warm to RT. After 2 h, the resulting pink precipitate was dissolved in EtOAc (5 mL) and the aqueous phase extracted with EtOAc (3 x 5 mL). The organic extracts were washed with saturated NaCl (10 mL) and the aqueous washing extracted with EtOAc (10 mL). The combined organic extracts were dried over MgSO₄ and concentrated *in vacuo* to obtain a dark orange oil. Purification by flash chromatography (0%, 17% EtOAc/*n*-hexane) afforded the *title compound* **27f** as a beige solid (176.6 mg, 99%). Mp. 42–44 °C. (Lit.¹⁰ 43–45 °C); *R_f* (17% EtOAc/*n*-hexane) 0.32; δ_H (400 MHz, CDCl₃) 2.58 (3H, s, 2–H), 7.09 (2H, dt, ³*J*_{3',2'} and ^{5',6'} 8.6 and ⁴*J*_{3',5'} 2.2, 3'–H and 5'–H), 7.97 (2H, dt, ³*J*_{2',3'} and ^{6',5'} 8.6 and ⁴*J*_{2',6'} 2.2, 2'–H and 6'–H); δ_C (100 MHz, CDCl₃) 26.5 (CH₃, C–1), 119.0 (2 x CH, C–3' and C–5'), 130.3 (2 x CH, C–2' and C–6'), 133.9 (C, C–1'), 144.9 (C, C–4'), 196.5 (C, C–1). The ¹H and ¹³C NMR spectra obtained was in agreement with that reported in the literature.¹¹




1-Azido-3-methoxybenzene (27g)


A suspension of 3-methoxyaniline (164 mg, 1.34 mmol) in H₂O (2.4 mL) was dissolved with concentrated HCl (12 M, 290 μL) at RT. The solution was cooled to 0 °C and a solution of NaNO₂ (93 mg, 1.35 mmol) in H₂O (2.9 mL) was added at a rate to maintain a reaction temperature < 5 °C. The light brown mixture was stirred for 15 minutes at 0 °C whereupon NaN₃ (104 mg, 1.60 mmol) was added slowly at 0 °C. The reaction mixture was allowed to warm to RT over 2 h. The aqueous phase was extracted with EtOAc (4 x 20 mL) and the combined organic extracts dried over Na₂SO₄ and concentrated *in vacuo* to get a brown oil. Purification by flash chromatography (0%, 9% to 20% EtOAc/*n*-hexane) afforded the *title compound* **27g** as a yellow oil (102 mg, 68%). *R_f* (9% EtOAc/*n*-hexane) 0.51; δ_H (300 MHz, CDCl₃) 3.80 (3H, s, OCH₃), 6.56 (1H, t, ⁴*J*_{2,4} and ^{2,6} 2.2, 2–H), 6.63–6.71 (2H, m, 4–H and 6–H), 7.26 (1H, t, ³*J*_{5,4} and ^{5,6} 8.1, 5–H); δ_C (75 MHz, CDCl₃) 55.3 (CH₃, OCH₃), 104.9 (CH, C–2), 110.7 (CH, C–4), 111.3 (CH, C–6), 130.4 (CH, C–5), 141.3 (C, C–1), 160.8 (C, C–3). The ¹H and ¹³C NMR spectra obtained was in agreement with that reported in the literature.¹¹





1-Azido-3-nitrobenzene (**27h**)


A suspension of 3-nitroaniline (172 mg, 1.25 mmol) in H₂O (2.4 mL) was dissolved with HCl (12 M, 270 μL) at RT. The yellow solution was cooled to 0 °C and a solution of NaNO₂ (98 mg, 1.42 mmol) in H₂O (3 mL) was added at a rate to maintain a reaction temperature < 5 °C and the reaction mixture stirred for 15 minutes at 0 °C. NaN₃ (104 mg, 1.60 mmol) was then added slowly at 0 °C and the reaction allowed to warm to RT over 2.5 h. The aqueous phase was extracted with EtOAc (4 x 10 mL) and the combined organic extracts dried over Na₂SO₄ and concentrated *in vacuo* to get an orange oil. Purification by flash chromatography (0%, 9% EtOAc/*n*-hexane) afforded the *title compound 27h* as a yellow crystalline solid (139 mg, 68%). Mp. 44-47 °C. (Lit.¹² 59-60 °C); *R_f* (9% EtOAc/*n*-hexane) 0.31; δ_H (400 MHz, CDCl₃) 7.33–7.36 (1H, m, 6-H), 7.54 (1H, t, ³*J*_{5,4 and 5,6} 8.0, 5-H) 7.89 (1H, t, ⁴*J*_{2,4 and 2,6} 2.2, 2-H), 7.99–8.02 (1H, m, 4-H); δ_C (100 MHz, CDCl₃) 114.1 (CH₃, C-2), 119.7 (CH, C-4), 124.9 (CH, C-6), 130.6 (CH, C-5), 142.0 (C, C-1), 149.3 (C, C-3). The ¹H and ¹³C NMR spectra obtained was in agreement with that reported in the literature.¹²



















Experimental and Characterization data for silyl-protected spiroacetal-triazoles **28a-h**


General Procedure for the Copper-Catalysed Azide-Alkyne Cycloaddition (CuAAC) of Acetylenic Spiroacetal **11** to Azides **27** (Procedure A)

To a mixture of acetylenic spiroacetal **11** (1.0 equiv.) and azide **27** (1.1-1.4 equiv.) in anhydrous toluene (0.050-0.086 M) under an argon atmosphere was added a catalytic quantity (a single crystal) of $\text{CuI}\cdot\text{P}(\text{OEt})_3$ and the reaction mixture heated to reflux for 1.0–1.5 h. Upon reaction completion by TLC analysis, the product was purified directly by flash chromatography (EtOAc–*n*-hexane) to yield only the 1,4-disubstituted regioisomer of the desired spiroacetal-triazole analogue **28**.




4-((2S,6S,8S)-8-((*tert*-Butyldiphenylsilyloxy)methyl)-1,7-dioxaspiro[5.5]undecan-2-yl)-1-octyl- 1H-1,2,3-triazole (**28a**)

The *title compound* **28a** (22.7 mg, 99%) was prepared as a pale yellow oil from acetylenic spiroacetal **11** (17.0 mg, 37.9 μmol), 1-azidooctane (**27a**) (8.1 mg, 52.2 μmol) and a single crystal of $\text{CuI}\cdot\text{P}(\text{OEt})_3$ in anhydrous toluene (750 μL) using Procedure A. The reaction mixture was purified by flash chromatography using EtOAc–*n*-hexane (0%, 9% to 17% EtOAc/*n*-hexane). $[\alpha]_D^{25}$ -15.0 (c 1.18 in CHCl_3); R_f (17% EtOAc/*n*-hexane) 0.29; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 2929 (C–H), 2857 (C–H), 1429 (C–H), 1113 (C–O–C), 982, 702 (C–H); δ_{H} (300 MHz, CDCl_3) 0.88 (3H, t, $^3J_{8'',7''}$ 6.7, 8''–H), 1.06 (9H, s, $\text{OSiPh}_2^t\text{Bu}$), 1.27–1.34 (11H, m, 3''–H, 4''–H, 5''–H, 6''–H, 7''–H and 9''–H_A), 1.44–1.72 (8H, m, 3''–H_A, 4''–H, 5''–H, 9''–H_B, 10''–H_A and 11''–H_A), 1.85–1.94 (3H, m, 2''–H and 10''–H_B), 2.02–2.14 (2H, m, 3''–H_B and 11''–H_B), 3.62 (1H, dd, $^2J_{\text{AB}}$ 10.3 and $^3J_{8''\text{-CH}_2\text{O},8''}$ 4.7, 8''–CH_AH_BO), 3.73 (1H, dd, $^2J_{\text{AB}}$ 10.3 and $^3J_{8''\text{-CH}_2\text{O},8''}$ 5.9, 8''–CH_AH_BO), 3.81–3.88 (1H, m, 8''–H), 4.32 (2H, t, $^3J_{1'',2''}$ 7.5, 1''–H), 4.98 (1H, dd, $^3J_{2',3'_{\text{ax}}}$ 11.6 and $^3J_{2',3'_{\text{eq}}}$ 1.8, 2'–H), 7.34–7.43 (7H, m, 5–H and Ph), 7.70–7.74 (4H, m, Ph); δ_{C} (75 MHz, CDCl_3) 14.0 (CH₃, C–11''), 18.5, 18.7 (2 x CH₂, C–4' and C–10'), 19.2 (C, $\text{OSiPh}_2^t\text{Bu}$), 22.6 (CH₂, C–7''), 26.6 (CH₂, C–3''), 26.8 (CH₃, $\text{OSiPh}_2^t\text{Bu}$), 27.0 (CH₂, C–9''), 28.9, 29.0 (2 x CH₂, C–4'' and C–5''), 30.3 (CH₂, C–2''), 30.8 (CH₂, C–3'), 31.7 (CH₂, C–6''), 35.1, 35.2 (2 x CH₂, C–5' and C–11'), 50.2 (CH₂, C–1''), 64.8 (CH, C–2'), 67.4 (CH₂, 8''–CH₂O), 70.3 (CH, C–8'), 96.6 (C, C–6'), 120.2 (CH, C–5), 127.5 (CH, Ph), 129.5 (CH, Ph), 133.8 (C, Ph), 135.6 (CH, Ph), 135.6 (CH, Ph), 150.2 (C, C–4); MS m/z (ESI+, MS₂+ (604)) 604 ([M + H]⁺, 40%), 586 (100), 568 ([M + H – ^tBu]⁺, 38), 526 ([M – Ph]⁺, 61), 508 ([M – Ph – H₂O]⁺, 87), 448 ([M – 2Ph – H]⁺, 73), 348 ([M – OTBDPS]⁺, 6), 330 (71), 312 (70), 302 (45), 284 (22); HRMS (ESI+): [M + H]⁺, found 604.3925. C₃₆H₅₄N₃O₃Si requires 604.3929.



14-(4-(8-((*tert*-Butyldiphenylsilyloxy)methyl)-1,7-dioxaspiro[5.5]undecan-2-yl)-1H-1,2,3-triazol-1-yl)tetradecane-2,5-dione (28b).


The *title compound* **28b** (10.1 mg, 58%) was prepared as a pale yellow oil from acetylenic spiroacetal **11** (10.5 mg, 24.3 μmol), diketo-azide **27b** (9.8 mg, 37.0 μmol) and a single crystal of $\text{CuI}\cdot\text{P}(\text{OEt})_3$ in anhydrous toluene (280 μL) using Procedure A. The reaction mixture was purified by flash chromatography using EtOAc–*n*-hexane (0 %, 25% to 33% EtOAc/*n*-hexane). $[\alpha]_D^{21}$ -19.5 (c 0.93 in CHCl_3); R_f (33% EtOAc/*n*-hexane) 0.15; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 2932 (C–H), 2857 (C–H), 1714 (C=O), 1428 (C–H), 1364, 1225, 1112 (C–O–C), 1086 (C–O–C), 982, 704; δ_{H} (300 MHz, CDCl_3) 1.05 (9H, s, $\text{OSiPh}_2^t\text{Bu}$), 1.24–1.33 (11H, m, 8–H, 9–H, 10–H, 11–H, 12–H, and 9'– H_A), 1.43–1.72 (10H, m, 7–H, 3'– H_A , 4'–H, 5'–H, 9'– H_B , 10'– H_A , and 11'– H_A), 1.89–1.93 (3H, m, 13–H and 10'– H_B), 2.06–2.12 (2H, 3'– H_B and 11'– H_B), 2.18 (3H, s, 1–H), 2.44 (2H, t, $^3J_{6,7}$ 7.4, 6–H), 2.63–2.73 (4H, m, 3–H and 4–H), 3.61 (1H, dd, $^2J_{AB}$ 10.3 and $^3J_{8\text{-CH}_2\text{O},8'}$ 4.7, 8'– $\text{CH}_A\text{H}_B\text{O}$), 3.72 (1H, dd, $^2J_{AB}$ 10.3 and $^3J_{8\text{-CH}_2\text{O},8'}$ 5.9, 8'– $\text{CH}_A\text{H}_B\text{O}$), 3.80–3.87 (1H, m, 8'–H), 4.32 (2H, t, $^3J_{14,13}$ 7.4, 14–H), 4.97 (1H, dd, $^3J_{2',3'\text{ax}}$ 11.5 and $^3J_{2',3'\text{eq}}$ 2.0, 2'–H), 7.32–7.40 (7H, m, 5''–H and Ph), 7.69–7.73 (4H, m, Ph); δ_{C} (75 MHz, CDCl_3) 18.5, 18.7 (2 x CH_2 , C–4' and C–10'), 19.3 (C, $\text{OSiPh}_2^t\text{Bu}$), 23.8 (CH_2 , C–7), 26.5 (CH_2 , C–12), 26.8 (CH_3 , $\text{OSiPh}_2^t\text{Bu}$), 27.1 (CH_2 , C–9'), 28.9, 29.1, 29.2, 29.2 (4 x CH_2 , C–8, C–9, C–10 and C–11), 29.9 (CH, C–1), 30.3 (CH_2 , C–13), 30.8 (CH_2 , C–3'), 35.1, 35.3 (2 x CH_2 , C–5' and C–11'), 36.0 (CH_2 , C–4), 36.9 (CH_2 , C–3), 42.8 (CH_2 , C–6), 50.2 (CH_2 , C–14), 64.8 (CH, C–2'), 67.4 (CH_2 , 8'– CH_2O), 70.3 (CH, C–8'), 96.6 (C, C–6'), 120.3 (CH, C–5''), 127.6 (CH, Ph), 129.5 (CH, Ph), 129.5 (CH, Ph), 133.9 (C, Ph), 135.6 (CH, Ph), 135.7 (CH, Ph), 150.2 (C, C–4''), 207.3 (C, C–2), 209.6 (C, C–5); MS m/z (ESI+, MS_2^+ (716)) 716 ($[\text{M} + \text{H}]^+$, 14%), 698 (53), 639 ($[\text{M} - \text{Ph}]^+$, 23), 620 (34), 542 (18), 442 (99), 424 (100); HRMS (ESI+): $[\text{M} + \text{H}]^+$, found 716.4464. $\text{C}_{42}\text{H}_{62}\text{N}_3\text{O}_5\text{Si}$ requires 716.4453.



11-(4-(8-((*tert*-Butyldiphenylsilyloxy)methyl)-1,7-dioxaspiro[5.5]undecan-2-yl)-1H-1,2,3-triazol-1-yl)undecan-2-one (28c)


The *title compound* **28c** (10.6 mg, 55%) was prepared as a pale yellow oil from acetylenic spiroacetal **11** (13.1 mg, 29.0 μmol), keto-azide **27c** (6.7 mg, 32.0 μmol) and a single crystal of $\text{CuI}\cdot\text{P}(\text{OEt})_3$ in anhydrous toluene (340 μL) using Procedure A. Purification was carried out by flash chromatography using EtOAc–*n*-hexane (0 %, 9% to 25% EtOAc/*n*-hexane). $[\alpha]_D^{21}$ -30.3 (c 1.06 in CHCl_3); R_f (25% EtOAc/*n*-hexane) 0.21; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 2930 (C–H), 2856 (C–H), 1715 (C=O), 1428

(C–H), 1361, 1112 (C–O–C), 1086 (C–O–C), 981, 702; δ_{H} (300 MHz, CDCl_3) 1.05 (9H, s, $\text{OSiPh}_2^t\text{Bu}$), 1.26–1.47 (11H, m, 5–H, 6–H, 7–H, 8–H, 9–H, and 9'– H_A), 1.49–1.77 (10H, m, 4–H, 3'– H_A , 4'–H, 5'–H, 9'– H_B , 10'– H_A , and 11'– H_A), 1.89–1.99 (3H, m, 10–H and 10'– H_B), 2.01–2.07 (2H, m, 3'– H_B and 11'– H_B), 2.13 (3H, s, 1–H), 2.41 (2H, t, $^3J_{3,4}$ 7.4, 3–H), 3.61 (1H, dd, $^2J_{\text{AB}}$ 10.3 and $^3J_{8'-\text{CH}_2\text{O},8'}$ 4.7, 8'– $\text{CH}_A\text{H}_B\text{O}$), 3.73 (1H, dd, $^2J_{\text{AB}}$ 10.3 and $^3J_{8'-\text{CH}_2\text{O},8'}$ 5.9, 8'– $\text{CH}_A\text{H}_B\text{O}$), 3.80–3.88 (1H, m, 8'–H), 4.32 (2H, t, $^3J_{11,10}$ 7.4, 11–H), 4.97 (1H, dd, $^3J_{2',3'_{\text{ax}}}$ 11.6 and $^3J_{2',3'_{\text{eq}}}$ 1.9, 2'–H), 7.32–7.40 (7H, m, 5''–H and Ph), 7.69–7.73 (4H, m, Ph); δ_{C} (75 MHz, CDCl_3) 18.5, 18.7 (2 x CH_2 , C–4' and C–10'), 19.3 (C, $\text{OSiPh}_2^t\text{Bu}$), 23.8 (CH_2 , C–4), 26.5 (CH_2 , C–9), 26.8 (CH_3 , $\text{OSiPh}_2^t\text{Bu}$), 27.0 (CH_2 , C–9'), 28.9, 29.1, 29.2, 29.2 (4 x CH_2 , C–5, C–6, C–7 and C–8), 29.8 (CH_3 , C–1), 30.3 (CH_2 , C–10), 30.8 (CH_2 , C–3'), 35.1, 35.2 (2 x CH_2 , C–5' and C–11'), 43.7 (CH_2 , C–3), 50.2 (CH_2 , C–11), 64.8 (CH, C–2'), 67.4 (CH_2 , 8– CH_2O), 70.3 (CH, C–8'), 96.6 (C, C–6'), 120.3 (CH, C–5''), 127.6 (CH, Ph), 129.5 (CH, Ph), 133.9 (C, Ph), 135.6 (CH, Ph), 135.7 (CH, Ph), 150.2 (C, C–4''), 209.2 (C, C–2); MS m/z (ESI+, MS_2+ (660)) 660 ($[\text{M} + \text{H}]^+$, 61%), 642 (100), 582 ($[\text{M} - \text{Ph}]^+$, 59), 564 (41), 504 (39), 386 (62), 358 (51); HRMS (ESI+): $[\text{M} + \text{H}]^+$, found 660.4182. $\text{C}_{39}\text{H}_{58}\text{N}_3\text{O}_4\text{Si}$ requires 660.4191.




1-(10-(tert-Butyldimethylsilyloxy)decyl)-4-((2S,6S,8S)-8-((tert-butyldiphenylsilyloxy)methyl)-1,7-dioxaspiro[5.5]undecan-2-yl)-1H-1,2,3-triazole (28d)

The *title compound* **28d** (11.9 mg, 57%) was prepared as a pale yellow oil from acetylenic spiroacetal **11** (12.2 mg, 27.2 μmol), TBDMS-protected-azide **27d** (9.4 mg, 30.0 μmol) and a single crystal of $\text{CuI}\cdot\text{P}(\text{OEt})_3$ in anhydrous toluene (420 μL) using Procedure A. The reaction mixture was purified by flash chromatography using EtOAc/n -hexane (0%, 11% to 17% EtOAc/n -hexane). $[\alpha]_{\text{D}}^{20}$ -15.9 (c 1.19 in CHCl_3); R_f (17% EtOAc/n -hexanes) 0.19; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 2930 (C–H), 2856 (C–H), 1428, 1113 (C–O–C), 983, 835, 702; δ_{H} (400 MHz, CDCl_3) 0.05 (6H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 0.89 (9H, s, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 1.05 (9H, s, $\text{OSiPh}_2^t\text{Bu}$), 1.26–1.33 (12H, m, 3–H, 4–H, 5–H, 6–H, 8–H, 9'– H_A , and 11'– H_A), 1.40–1.72 (11H, m, 7–H, 9–H, 3'– H_A , 4'–H, 5'–H, 9'– H_B and 10'– H_A), 1.87–1.93 (3H, m, 2–H and 10'– H_B), 2.02–2.17 (2H, m, 3'– H_B and 11'– H_B), 3.59 (2H, t, $^3J_{10,9}$ 6.6, 10–H), 3.59–3.64 (1H, m, 8'– $\text{CH}_A\text{H}_B\text{O}$), 3.72 (1H, dd, $^2J_{\text{AB}}$ 10.3 and $^3J_{8'-\text{CH}_2\text{O},8'}$ 5.9, 8'– $\text{CH}_A\text{H}_B\text{O}$), 3.81–3.87 (1H, m, 8'–H), 4.32 (2H, t, $^3J_{1,2}$ 7.4, 1–H), 4.97 (1H, dd, $^3J_{2',3'_{\text{ax}}}$ 11.5 and $^3J_{2',3'_{\text{eq}}}$ 2.2, 2'–H), 7.32–7.42 (7H, m, 5''–H and Ph), 7.69–7.73 (4H, m, Ph); δ_{C} (100 MHz, CDCl_3) -5.3 (2 x CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 18.4 (C, $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 18.5, 18.7 (2 x CH_2 , C–4' and C–10'), 19.3 (C, $\text{OSiPh}_2^t\text{Bu}$), 25.8 (CH_2 , C–3), 26.0 (CH_3 , $\text{OSi}(\text{CH}_3)_2^t\text{Bu}$), 26.6 (CH_2 , C–7), 26.8 (CH_3 , $\text{OSiPh}_2^t\text{Bu}$), 27.0 (CH_2 , C–9'), 29.0, 29.3, 29.4, 29.5 (4 x CH_2 , C–4, C–5, C–6 and C–8), 30.3 (CH_2 , C–2), 30.8 (CH_2 , C–3') 32.9 (CH_2 , C–9), 35.1, 35.2 (2 x CH_2 , C–5' and C–11'), 50.3 (CH_2 , C–1), 63.3 (CH_2 , C–10), 64.8 (CH, C–2'), 67.4 (CH_2 , 8'– CH_2O), 70.3 (CH, C–8'), 96.6 (C, C–6'), 120.3 (CH, C–5''), 127.6 (CH, Ph), 129.5 (CH, Ph), 133.9 (C, Ph), 135.6 (CH, Ph), 135.7 (CH, Ph), 150.2 (C, C–4''); MS m/z (ESI+, MS_2+ (762)) 762 ($[\text{M} + \text{H}]^+$, 59%), 744 (100), 684 ($[\text{M} - \text{Ph}]^+$, 86), 666 (55), 606 ($[\text{M} - \text{OTBDPS} + \text{H}_2\text{O}]^+$, 46), 506 ($[\text{M} - \text{OTBDPS}]^+$, 3), 488 (25), 470 (23), 442 (16); HRMS (ESI+): $[\text{M} + \text{H}]^+$, found 762.5057. $\text{C}_{44}\text{H}_{72}\text{N}_3\text{O}_4\text{Si}_2$ requires 762.5056.



Methyl 6-(4-((2S,6S,8S)-8-((tert-butyl)diphenylsilyloxy)methyl)-1,7-dioxaspiro[5.5]undecan-2-yl)-1H-1,2,3-triazol-1-yl)hexanoate (28e)


The *title compound* **28e** (19.6 mg, 78%) was prepared as a pale yellow oil from acetylenic spiroacetal **11** (18.2 mg, 40.6 μmol), methyl 6-azidohexanoate (**27e**) (6.9 mg, 40.3 μmol) and a single crystal of $\text{CuI}\cdot\text{P}(\text{OEt})_3$ in anhydrous toluene (800 μL) using Procedure A. The reaction mixture was purified by flash chromatography using EtOAc-*n*-hexane (0%, 17% to 33% EtOAc/*n*-hexane). $[\alpha]_D^{26}$ -19.7 (c 1.12 in CHCl_3); R_f (33% EtOAc/*n*-hexanes) 0.28; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 2936 (C-H), 2858 (C-H), 1737 (C=O), 1429, 1112 (C-O-C), 1086, 982, 703; δ_{H} (300 MHz, CDCl_3) 1.05 (9H, s, $\text{OSiPh}_2^t\text{Bu}$), 1.23–1.31 (1H, m, 9'-H_A), 1.34–1.52 (4H, m, 4-H, 10'-H_A and 11'-H_A), 1.55–1.74 (8H, m, 3-H, 3'-H_A, 4'-H, 5'-H, 9'-H_B), 1.85–1.99 (3H, m, 5-H and 10'-H_B), 2.02–2.17 (2H, m, 3'-H_B and 11'-H_B), 2.32 (2H, t, $^3J_{2,3}$ 7.4, 2-H), 3.62 (1H, dd, $^2J_{\text{AB}}$ 10.3 and $^3J_{8'-\text{CH}_2\text{O},8'}$ 4.6, 8'-CH_AH_BO), 3.66 (3H, s, OCH₃), 3.73 (1H, dd, $^2J_{\text{AB}}$ 10.3 and $^3J_{8'-\text{CH}_2\text{O},8'}$ 5.9, 8'-CH_AH_BO), 3.81–3.88 (1H, m, 8'-H), 4.33 (2H, t, $^3J_{6,5}$ 7.3, 6-H), 4.97 (1H, dd, $^3J_{2,3^{\text{ax}}}$ 11.5 and $^3J_{2,3^{\text{eq}}}$ 1.6, 2'-H), 7.31–7.43 (7H, m, 5''-H and Ph), 7.69–7.74 (4H, m, Ph); δ_{C} (75 MHz, CDCl_3) 18.5, 18.6 (2 x CH₂, C-4' and C-10'), 19.2 (C, $\text{OSiPh}_2^t\text{Bu}$), 24.2 (CH₂, C-3), 26.0 (CH₂, C-4), 26.8 (CH₃, $\text{OSiPh}_2^t\text{Bu}$), 27.0 (CH₂, C-9'), 30.0 (CH₂, C-5), 30.8 (CH₂, C-3'), 33.7 (CH₂, C-2), 35.1, 35.2 (2 x CH₂, C-5' and C-11'), 49.9 (CH₂, C-6), 51.5 (CH₃, OCH₃), 64.8 (CH, C-2'), 67.4 (CH₂, 8'-CH₂O), 70.3 (CH, C-8'), 96.6 (C, C-6'), 120.3 (CH, C-5''), 127.5 (CH, Ph), 129.5 (CH, Ph), 129.5 (CH, Ph), 133.8 (C, Ph), 135.6 (CH, Ph), 135.7 (CH, Ph), 150.3 (C, C-4''), 173.8 (C, C-1); MS m/z (ESI⁺, MS₂⁺ (620)) 620 ([M + H]⁺, 52%), 602 (100), 542 ([M - Ph]⁺, 54), 524 ([M - Ph - H₂O]⁺, 61), 464 ([M - 2Ph - H]⁺, 52), 346 (52), 328 (53), 318 (36), 129 ([C₇H₁₃O₂]⁺, 5); HRMS (ESI⁺): [M + H]⁺, found 620.3492. C₃₅H₅₀N₃O₅Si requires 620.3514.



1-(4-(4-((2S,6S,8S)-8-((tert-Butyl)diphenylsilyloxy)methyl)-1,7-dioxaspiro[5.5]undecan-2-yl)-1H-1,2,3-triazol-1-yl)phenyl)ethanone (28f)

The *title compound* **28f** (18.8 mg, 81%) was prepared as a pale yellow oil from acetylenic spiroacetal **11** (16.9 mg, 38.0 μmol), 1-(4-azidophenyl)ethanone (**27f**) (6.9 mg, 40.3 μmol) and a single crystal of $\text{CuI}\cdot\text{P}(\text{OEt})_3$ in anhydrous toluene (600 μL) using Procedure A. The reaction mixture was purified by


flash chromatography using EtOAc-*n*-hexane (0 %, 9% to 25% EtOAc/*n*-hexane). $[\alpha]_D^{21}$ -30.0 (c 0.99 in CHCl₃); R_f (25% EtOAc/*n*-hexanes) 0.27; IR (film) $\nu_{\max}/\text{cm}^{-1}$ 2933 (C-H), 2857 (C-H), 1689 (C=O), 1605 (C=C), 1429 (C-H), 1264 (C-O), 1113 (C-O-C), 983, 703; δ_H (300 MHz, CDCl₃) 1.07 (9H, s, OSiPh₂^tBu), 1.22–1.36 (1H, m, 9''-H_A), 1.40–1.56 (2H, m, 10''-H_A and 11''-H_A), 1.59–1.75 (6H, m, 3''-H_A, 4''-H, 5''-H and 9''-H_B), 1.85–2.00 (1H, m, 10''-H_B), 2.04–2.17 (2H, m, 3''-H_B and 11''-H_B), 2.66 (3H, s, 2-H), 3.63 (1H, dd, $^2J_{AB}$ 10.3 and $^3J_{8'-\text{CH}_2\text{O},8'}$ 4.6, 8''-CH_AH_BO), 3.75 (1H, dd, $^2J_{AB}$ 10.3 and $^3J_{8'-\text{CH}_2\text{O},8'}$ 6.1, 8''-CH_AH_BO), 3.82–3.88 (1H, m, 8''-H), 5.08 (1H, dd, $^3J_{2,3'_{\text{ax}}}$ 11.5 and $^3J_{2,3'_{\text{eq}}}$ 1.7, 2''-H), 7.31–7.42 (6H, m, Ph), 7.69–7.74 (4H, m, Ph), 7.89–7.93 (3H, m, 5'''-H, 3'-H and 5'-H), 8.13 (2H, d, $^3J_{2,3'}$ and $6',5'$ 8.9, 2'-H and 6'-H); δ_C (75 MHz, CDCl₃) 18.5, 18.6 (2 x CH₂, C-4'' and C-10''), 19.2 (C, OSiPh₂^tBu), 25.6 (CH₃, C-2), 26.8 (CH₃, OSiPh₂^tBu), 27.0 (CH₂, C-9''), 30.9 (CH₂, C-3''), 35.1, 35.2 (2 x CH₂, C-5'' and C-11''), 64.7 (CH, C-2''), 67.4 (CH₂, 8''-CH₂O), 70.5 (CH, C-8''), 96.7 (C, C-6''), 118.5 (CH, C-5'''), 120.0 (2 x CH, C-3' and C-5'), 127.6 (CH, Ph), 129.5 (CH, Ph), 129.5 (CH, Ph), 130.0 (2 x CH C-2' and C-6'), 133.8 (C, Ph), 135.6 (CH, Ph), 135.7 (CH, Ph), 136.7 (C, C-1'), 140.3 (C, C-4'), 151.6 (C, C-4'''), 196.6 (C, C-1); MS m/z (ESI+, MS₂+ (610)) 610 ([M + H]⁺, 47%), 592 (43), 564 (19), 532 ([M - Ph]⁺, 52), 514 (63), 504 (48), 486 (34), 454 ([M - 2Ph - H]⁺, 46), 369 ([M - OTBDPS]⁺, 10), 336 (54), 318 (33), 308 (100); HRMS (ESI+): [M + H]⁺, found 610.3100. C₃₆H₄₄N₃O₄Si requires 610.3096.



4-((2S,6S,8S)-8-((*tert*-Butyldiphenylsilyloxy)methyl)-1,7-dioxaspiro[5.5]undecan-2-yl)-1-(3-methoxyphenyl)-1H-1,2,3-triazole (28g)


The *title compound* **28g** (15.0 mg, 65%) was prepared as a pale yellow oil from acetylenic spiroacetal **11** (17.4 mg, 38.7 μmol), 1-azido-3-methoxybenzene (**27g**) (6.8 mg, 46.0 μmol) and a single crystal of CuI•P(OEt)₃ in anhydrous toluene (620 μL) using Procedure A. The reaction mixture was purified by flash chromatography using EtOAc-*n*-hexane (0%, 9% to 17% EtOAc/*n*-hexane). $[\alpha]_D^{23}$ -30.5 ° (c 1.27 in CHCl₃); R_f (17% EtOAc/*n*-hexanes) 0.30; IR (film) $\nu_{\max}/\text{cm}^{-1}$ 2982 (C-H), 2971 (C-H), 1610 (C=C), 1226 (C-H), 1113 (C-O-C), 1067 (C-O), 1046 (C-O), 982, 702; δ_H (400 MHz, CDCl₃) 1.07 (9H, s, OSiPh₂^tBu), 1.22–1.34 (1H, m, 9'-H_A), 1.43–1.55 (2H, m, 10'-H_A and 11'-H_A), 1.57–1.75 (6H, m, 3'-H_A, 4'-H, 5'-H and 9'-H_B), 1.87–1.99 (1H, m, 10'-H_B), 2.10–2.17 (2H, m, 3'-H_B and 11'-H_B), 3.63 (1H, dd, $^2J_{AB}$ 10.4 and $^3J_{8'-\text{CH}_2\text{O},8'}$ 4.6, 8'-CH_AH_BO), 3.75 (1H, dd, $^2J_{AB}$ 10.4 and $^3J_{8'-\text{CH}_2\text{O},8'}$ 6.1, 8'-CH_AH_BO), 3.83–3.87 (1H, m, 8'-H), 3.89 (3H, s, PhOCH₃), 5.06 (1H, dd, $^3J_{2,3'_{\text{ax}}}$ 11.6 and $^3J_{2,3'_{\text{eq}}}$ 1.9, 2'-H), 6.97 (1H, dd, $^3J_{4,5}$ 8.3 and $^4J_{4,2}$ 2.5, 4-H), 7.27–7.29 (1H, m, 2-H), 7.32–7.43 (8H, m, 5-H, 6-H and Ph), 7.70–7.75 (4H, m, Ph), 7.85 (1H, s, 5''-H); δ_C (100 MHz, CDCl₃) 18.5, 18.7 (2 x CH₂, C-4' and C-10'), 19.3 (C, OSiPh₂^tBu), 26.8 (CH₃, OSiPh₂^tBu), 27.0 (CH₂, C-9'), 30.9 (CH₂, C-3'), 35.1, 35.2 (2 x CH₂, C-5' and C-11'), 55.6 (CH₃, PhOCH₃), 64.8 (CH, C-2'), 67.4 (CH₂, 8'-CH₂O), 70.4 (CH, C-8'), 96.7 (C, C-6'), 106.4 (CH, C-6), 112.4 (CH, C-2), 114.4 (CH, C-4), 118.9 (CH, C-5''), 127.6 (CH, Ph), 129.5 (CH, Ph), 129.5 (CH, Ph), 130.4 (CH, C-5), 133.8 (C, Ph), 135.6 (CH, Ph), 135.7 (CH, Ph), 138.3 (C, C-1), 151.0 (C, C-4''), 160.6 (C, C-3); MS m/z (ESI+, MS₂+ (598)) 598 ([M + H]⁺, 16%), 580 (50), 552 (21), 520


([M - Ph]⁺, 31), 502 (70), 492 (35), 474 (30), 442 ([M - 2Ph - H]⁺, 37), 324 (53), 306 (37), 296 (100); HRMS (ESI⁺): [M + H]⁺, found 598.3082. C₃₅H₄₄N₃O₄Si requires 598.3096.





4-((2S,6S,8S)-8-((*tert*-Butyldiphenylsilyloxy)methyl)-1,7-dioxaspiro[5.5]undecan-2-yl)-1-(3-nitrophenyl)-1H-1,2,3-triazole (**28h**)


The *title compound* **28h** (18.4 mg, 75%) was prepared as a pale yellow oil from acetylenic spiroacetal **11** (17.9 mg, 39.9 μmol), 3-azido-1-nitrobenzene (**27h**) (7.3 mg, 45.0 μmol) and a single crystal of CuI•P(OEt)₃ in anhydrous toluene (640 μL) using Procedure A. The reaction mixture was purified by flash chromatography using EtOAc-*n*-hexane (0%, 9% to 17% EtOAc/*n*-hexane to 33% *n*-hexane/EtOAc). [α]_D²⁴ -39.9 (c 0.99 in CHCl₃); R_f (33% *n*-hexane/EtOAc) 0.29; IR (film) ν_{max}/cm⁻¹ 2931 (C-H), 2857 (C-H), 1537 (N=O), 1428 (C-H), 1350 (N=O), 1112 (C-O-C), 702; δ_H (400 MHz, CDCl₃) 1.07 (9H, s, OSiPh₂^tBu), 1.22–1.35 (1H, m, 9'-H_A), 1.45–1.59 (2H, m, 10'-H_A and 11'-H_A), 1.62–1.76 (6H, m, 3'-H_A, 4'-H, 5'-H and 9'-H_B), 1.89–1.99 (1H, m, 10'-H_B), 2.11–2.21 (2H, m, 3'-H_B and 11'-H_B), 3.64 (1H, dd, ²J_{AB} 10.4 and ³J_{8'-CH₂O,8'} 4.5, 8'-CH_AH_BO), 3.75 (1H, dd, ²J_{AB} 10.4 and ³J_{8'-CH₂O,8'} 6.2, 8'-CH_AH_BO), 3.82–3.88 (1H, m, 8'-H), 5.10 (1H, dd, ³J_{2',3'ax} 11.8 and ³J_{2',3'eq} 1.8, 2'-H), 7.33–7.42 (6H, m, Ph), 7.70–7.77 (5H, m, 5-H and Ph), 7.97 (1H, s, 5''-H), 8.21–8.24 (1H, m, 6-H), 8.29–8.31 (1H, m, 4-H), 8.60 (1H, t, ⁴J_{2,4} and ^{2,6} 2.1, 2-H); δ_C (100 MHz, CDCl₃) 18.5, 18.6 (2 x CH₂, C-4' and C-10'), 19.3 (C, OSiPh₂^tBu), 26.8 (CH₃, OSiPh₂^tBu), 26.9 (CH₂, C-9'), 30.9 (CH₂, C-3'), 35.1, 35.2 (2 x CH₂, C-5' and C-11'), 64.7 (CH, C-2'), 67.3 (CH₂, 8'-CH₂O), 70.6 (CH, C-8'), 96.7 (C, C-6'), 115.1 (CH, C-2), 118.6 (CH, C-5''), 122.9 (CH, C-4), 126.0 (CH, C-6), 127.6 (CH, Ph), 129.5 (CH, Ph), 129.5 (CH, Ph), 130.9 (CH, C-5), 133.8 (C, Ph), 133.8 (C, Ph), 135.6 (CH, Ph), 135.6 (CH, Ph), 138.0 (C, C-1), 148.9 (C, C-3), 152.0 (C, C-4''); MS *m/z* (ESI⁺, MS₂⁺ (613)) 613 ([M + H]⁺, 67%), 595 (10), 567 ([M - NO₂ + H]⁺, 4), 535 ([M - Ph]⁺, 100), 517 (29), 507 (57), 489 ([M - Ph - NO₂]⁺, 12), 457 ([M - 2Ph - H]⁺, 55), 357 ([M - OTBDPS]⁺, 11), 311 ([M - OTBDPS - NO₂]⁺, 64); HRMS (ESI⁺): [M + H]⁺, found 613.2828. C₃₄H₄₁N₄O₅Si requires 613.2841.













































Experimental and Characterization data for hydroxymethyl spiroacetal-triazoles **10a-h**


General Procedure for Deprotection of Silyl Protected Spiroacetal-Triazole Analogues **28** (Procedure B)

3HF•NEt₃ (2.4-2.8 μL per μmol of spiroacetal-triazole) was added to a solution of silyl-protected spiroacetal-triazole **28** (1.0 equiv.) in anhydrous THF (0.042-0.078 M) under an argon atmosphere. After stirring at RT for 24 h, a second portion of 3HF•NEt₃ (2.1-2.8 μL per μmol of spiroacetal-triazole) was added and the mixture was stirred at RT for an additional 24 h. Saturated NaHCO₃ was added dropwise (2 mL) and the aqueous phase extracted with EtOAc (4 x 5-10 mL). The combined organic extracts were dried over Na₂SO₄ and concentrated *in vacuo*. Purification by flash chromatography (EtOAc-*n*-hexane) afforded the desired hydroxymethyl spiroacetal-triazole analogue **10**.




((2*S*,6*S*,8*S*)-8-(1-Octyl-1*H*-1,2,3-triazol-4-yl)-1,7-dioxaspiro[5.5]undecan-2-yl)methanol (**10a**)

The *title compound* **10a** (11.7 mg, 85%) was prepared as a pale yellow oil from TBDPS-protected triazole **28a** (22.7 mg, 37.6 μmol) and 3HF•NEt₃ (100 μL, 2.66 μL/μmol, then 80 μL, 2.13 μL/μmol) in anhydrous THF (890 μL) using Procedure B. Purification was carried out by flash chromatography using EtOAc-*n*-hexane (0%, 25% EtOAc/*n*-hexane to 25% *n*-hexane/EtOAc) [α]_D²⁴ -0.8 (c 1.17 in CHCl₃); *R*_f (25% *n*-hexane/EtOAc) 0.29; IR (film) ν_{\max} /cm⁻¹ 3374 (br, O-H), 2930 (C-H), 2857 (C-H), 1438 (C-H), 1224, 1203, 1054 (C-O), 981 (C-O-C); δ_{H} (300 MHz, CDCl₃) 0.87 (3H, t, ³*J*_{8'',7''} 6.8, 8''-H), 1.26-1.36 (11H, m, 3''-H, 4''-H, 5''-H, 6''-H, 7''-H and 3-H_A), 1.38-1.61 (5H, m, 3-H_B, 4-H_A, 5-H_A, and 10-H), 1.64-1.71 (3H, m, 9-H_A and 11-H), 1.83-2.01 (4H, m, OH, 4-H_B and 2''-H), 2.04-2.08 (2H, m, 5-H_B and 9-H_B), 3.53 (1H, dd, ²*J*_{AB} 11.3 and ³*J*_{2-CH_AH_BO} 6.5, 2-CH_AH_BO), 3.64 (1H, br d, ²*J*_{AB} 11.3, 2-CH_AH_BO), 3.77-3.86 (1H, m, 2-H), 4.31 (2H, t, ³*J*_{1'',2''} 7.3, 1''-H), 4.89 (1H, dd, ³*J*_{8,9ax} 11.5 and ³*J*_{8,9eq} 2.0, 8-H), 7.45 (1H, s, 5'-H); δ_{C} (75 MHz, CDCl₃) 14.0 (CH₃, C-8''), 18.2, 18.7 (2 x CH₂, C-4 and C-10), 22.6 (CH₂, C-7''), 26.4 (CH₂, C-3), 26.5 (CH₂, C-3''), 28.9, 29.0 (2 x CH₂, C-4'' and C-5''), 30.3 (CH₂, C-2''), 30.8 (CH₂, C-9), 31.7 (CH₂, C-6''), 35.0, 35.3 (2 x CH₂, C-5 and C-11), 50.3 (CH₂, C-1''), 65.0 (CH, C-8), 66.2 (CH₂, 2-CH₂O), 69.9 (CH, C-2), 96.6 (C, C-6), 120.3 (CH, C-5'), 149.9 (C, C-4'); MS *m/z* (ESI+, MS₂+ (366)) 366 ([M + H]⁺, 13%), 348 ([M - OH]⁺, 100), 330 (17), 320 ([M - OH - Et]⁺, 22), 302 (6), 192 (30); HRMS (ESI+): [M + H]⁺, found 366.2746. C₂₀H₃₆N₃O₃ requires 366.2751.




14-(4-((2S,6S,8S)-8-(Hydroxymethyl)-1,7-dioxaspiro[5.5]undecan-2-yl)-1H-1,2,3-triazol-1-yl)tetradecane-2,5-dione (10b)

The *title compound* **10b** (3.2 mg, 54%) was prepared as a pale yellow oil from TBDPS-protected triazole **28b** (9.0 mg, 12.6 μmol) and $3\text{HF}\cdot\text{NEt}_3$ (2 x 30 μL , 2.40 $\mu\text{L}/\mu\text{mol}$) in anhydrous THF (300 μL) using Procedure B. Purification was carried out by flash chromatography using EtOAc–*n*-hexane (25% EtOAc/*n*-hexane to 100% EtOAc). $[\alpha]_{\text{D}}^{20}$ -22.4 (c 0.32 in CHCl_3); R_f (100% EtOAc) 0.25; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 3416 (br, O–H), 2931 (C–H), 2856 (C–H), 1711 (C=O), 1366, 1224, 1053 (C–O–C), 980; δ_{H} (400 MHz, CDCl_3) 1.25–1.35 (11H, m, 8–H, 9–H, 10–H, 11–H, 12–H and 9'– H_A), 1.37–1.73 (10H, m, 7–H, 3'– H_A , 4'–H, 5'–H, 9'– H_B , 10'– H_A and 11'– H_A), 1.86–1.97 (3H, m, 13–H and 10'– H_B), 1.98–2.10 (3H, m, OH, 3'– H_B , and 11'– H_B), 2.18 (3H, s, 1–H), 2.44 (2H, t, $^3J_{6,7}$ 7.4, 6–H), 2.65–2.72 (4H, m, 3–H and 4–H), 3.53 (1H, dd, $^2J_{AB}$ 11.0 and $^3J_{8\text{-CH}_2\text{O},8}$ 6.5, 8'– $\text{CH}_A\text{H}_B\text{O}$), 3.63–3.66 (1H, m, 8'– $\text{CH}_A\text{H}_B\text{O}$), 3.79–3.85 (1H, m, 8'–H), 4.31 (2H, t, $^3J_{14,13}$ 7.4, 14–H), 4.90 (1H, dd, $^3J_{2',3\text{ax}}$ 11.7 and $^3J_{2',3\text{eq}}$ 2.0, 2'–H), 7.45 (1H, s, 5''–H); δ_{C} (75 MHz, CDCl_3) 18.2, 18.8 (2 x CH_2 , C–4' and C–10'), 23.8 (CH_2 , C–7), 26.4 (CH_2 , C–9'), 26.5 (CH_2 , C–12), 28.9, 29.1, 29.1 29.2 (4 x CH_2 , C–8, C–9, C–10 and C–11), 29.9 (CH_3 , C–1), 30.3 (CH_2 , C–13), 30.8 (CH_2 , C–3'), 35.0, 35.3 (2 x CH_2 , C–5' and C–11'), 36.1 (CH_2 , C–4), 36.9 (C–3), 42.8 (CH_2 , C–6), 50.3 (CH_2 , C–14), 65.1 (CH, C–2'), 66.2 (CH_2 , 8'– CH_2O), 69.9 (CH, C–8'), 96.6 (C, C–6'), 120.3 (CH, C–5''), 150.0 (C, C–4''), 207.3 (C, C–2), 209.6 (C, C–5); MS m/z (ESI+, MS_2^+ (500)) 500 ($[\text{M} + \text{Na}]^+$, 100%), 472 ($[\text{M} - \text{Ac}]^+$, 4), 442 (47), 342 (19), 316 (4), 288 (30); HRMS (ESI+): $[\text{M} + \text{H}]^+$, found 478.3283. $\text{C}_{26}\text{H}_{44}\text{N}_3\text{O}_5$ requires 478.3275.




11-(4-((2S,6S,8S)-8-(Hydroxymethyl)-1,7-dioxaspiro[5.5]undecan-2-yl)-1H-1,2,3-triazol-1-yl)undecane-2-one (10c)

The *title compound* **10c** (3.7 mg, 52%) was prepared as a pale yellow oil from TBDPS-protected triazole **28c** (11.2 mg, 17.0 μmol) and $3\text{HF}\cdot\text{NEt}_3$ (2 x 40 μL , 2.37 $\mu\text{L}/\mu\text{mol}$) in anhydrous THF (400 μL) using Procedure B. Purification was carried out by flash chromatography using EtOAc–*n*-hexane (33% EtOAc/*n*-hexane to 100% EtOAc). $[\alpha]_{\text{D}}^{20}$ -7.5 (c 0.41 in CHCl_3); R_f (100% EtOAc) 0.33; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 3399 (br, O–H), 2931 (C–H), 2855 (C–H), 1713 (C=O), 1438 (C–H), 1366, 1223, 1053 (C–O–C), 981; δ_{H} (300 MHz, CDCl_3) 1.25–1.43 (12H, m, 5–H, 6–H, 7–H, 8–H, 9–H, 9'– H_A , and 11'– H_A), 1.45–1.73 (9H, m, 4–H, 3'– H_A , 4'–H, 5'–H, 9'– H_B , and 10'– H_A), 1.85–1.98 (3H, m, 10–H, and 10'– H_B), 1.99–2.10 (2H, m, 3'– H_B , and 11'– H_B), 2.13 (3H, s, 1–H),



Methyl 6-(4-((2S,6S,8S)-8-(hydroxymethyl)-1,7-dioxaspiro[5.5]undecan-2-yl)-1H-1,2,3-triazol-1-yl)hexanoate (10e)


The *title compound* **10e** (3.2 mg, 38%) was prepared as a pale yellow oil from TBDPS-protected triazole **28e** (13.6 mg, 21.9 μmol) and $3\text{HF}\cdot\text{NEt}_3$ (60 μL , 2.74 $\mu\text{L}/\mu\text{mol}$, then 50 μL , 2.28 $\mu\text{L}/\mu\text{mol}$) in anhydrous THF (520 μL) using Procedure B. Purification was carried out by flash chromatography using EtOAc-*n*-hexane (0%, 25% EtOAc/*n*-hexane to 100% EtOAc). $[\alpha]_{\text{D}}^{24}$ -10.8 (c 0.42 in CHCl_3); R_f (100% EtOAc) 0.24; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 2936 (C-H), 2872 (C-H), 1730 (C=O), 1543, 1436 (C-H), 1224 (C(=O)-O); δ_{H} (300 MHz, CDCl_3) 1.31–1.62 (7H, m, 4-H, 5'-H, 9'-H and 11'-H_A), 1.63–1.73 (6H, m, 3-H, 3'-H_A, 4'-H and 10'-H_A), 1.86–2.01 (4H, m, OH, 5-H and 10'-H_B), 2.02–2.17 (2H, m, 3'-H_B and 11'-H_B), 2.32 (2H, t, $^3J_{2,3}$ 7.4, 2-H), 3.53 (1H, dd, $^2J_{\text{AB}}$ 11.3 and $^3J_{8'-\text{CH}_2\text{O},8'}$ 6.5, 8'-CH_AH_BO), 3.63–3.67 (4H, m, OCH₃ and 8'-CH_AH_BO), 3.77–3.85 (1H, m, 8'-H), 4.33 (2H, t, $^3J_{6,5}$ 7.2, 6-H), 4.90 (1H, d, $^3J_{2',3'_{\text{ax}}}$ 11.2, 2'-H), 7.46 (1H, s, 5''-H); δ_{C} (100 MHz, CDCl_3) 18.2, 18.7 (2 x CH₂, C-4' and C-10'), 24.2 (CH₂, C-3), 26.0 (CH₂, C-4), 26.4 (CH₂, C-9'), 30.0 (CH₂, C-5), 30.8 (CH₂, C-3'), 33.7 (CH₂, C-2), 35.0, 35.3 (2 x CH₂, C-5' and C-11'), 50.0 (CH₂, C-6), 51.5 (CH₃, OCH₃), 65.0 (CH, C-2'), 66.2 (CH₂, 8'-CH₂O), 69.9 (CH, C-8'), 96.7 (C, C-6'), 120.4 (CH, C-5''), 150.1 (C, C-4''), 173.8 (C, C-1); MS m/z (ESI+, MS₂+ (382)) 382 ([M + H]⁺, 13%), 364 ([M - OH]⁺, 100), 346 (17), 336 (17), 208 (21), 129 (5); HRMS (ESI+): [M + H]⁺, found 382.2335. C₁₉H₃₂N₃O₅ requires 382.2336.



1-(4-(4-((2S,6S,8S)-8-(Hydroxymethyl)-1,7-dioxaspiro[5.5]undecan-2-yl)-1H-1,2,3-triazol-1-yl)phenyl)ethanone (10f)


The *title compound* **10f** (6.8 mg, 59%) was prepared as a pale yellow oil from TBDPS-protected triazole **28f** (18.8 mg, 30.8 μmol) and $3\text{HF}\cdot\text{NEt}_3$ (2 x 80 μL , 2.60 $\mu\text{L}/\mu\text{mol}$) in anhydrous THF (730 μL) using Procedure B. Purification was carried out by flash chromatography using EtOAc-*n*-hexane (0%, 25% EtOAc/*n*-hexane to 20% *n*-hexane/EtOAc). $[\alpha]_{\text{D}}^{23}$ -65.2 (c 0.68 in CHCl_3); R_f (20% *n*-hexanes/EtOAc) 0.27; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 3411 (O-H), 2939 (C-H), 2868 (C-H), 1684 (C=O), 1605 (C=C), 1265 (C-O), 980; δ_{H} (300 MHz, CDCl_3) 1.30–1.44 (1H, m, 9''-H_A), 1.47–1.58 (2H, m, 9''-H_B and 11''-H_A), 1.59–1.76 (6H, m, 3''-H_A, 4''-H, 5''-H and 10''-H_A), 1.87–2.07 (1H, m, 10''-H_B), 2.09–2.20 (2H, m, 3''-H_B and 11''-H_B), 2.66 (3H, s, 2-H), 3.53–3.58 (1H, m, 8''-CH_AH_BO), 3.65–3.68 (1H, m, 8''-CH_AH_BO), 3.80–3.88 (1H, m, 8''-H), 5.00 (1H, dd, $^3J_{2',3'_{\text{ax}}}$ 11.5

and $^3J_{2',3''\text{eq}}$ 1.8, 2''-H), 7.89 (2H, d, $^3J_{3',2'}$ and $5',6'$ 8.9, 3'-H and 5'-H), 7.99 (1H, s, 5'''-H), 8.12 (2H, d, $^3J_{2',3'}$ and $6',5'$ 8.9, 2'-H and 6'-H); δ_{C} (75 MHz, CDCl_3) 18.2, 18.7 (2 x CH_2 , C-4'' and C-10''), 26.4 (CH_2 , C-9''), 26.7 (CH_3 , C-2), 30.9 (CH_2 , C-3''), 35.0, 35.3 (2 x CH_2 , C-5'' and C-11''), 65.0 (CH , C-2''), 66.2 (CH_2 , 8''- CH_2O), 70.1 (CH , C-8''), 96.8 (C, C-6''), 118.6 (CH , C-5'''), 120.0 (2 x CH , C-3' and C-5'), 130.0 (2 x CH , C-2' and C-6'), 136.7 (C, C-1'), 140.3 (C, C-4'), 151.4 (C, C-4'''), 196.6 (C, C-1); MS m/z (ESI+) 394 ($[\text{M} + \text{Na}]^+$, 100%), 372 ($[\text{M} + \text{H}]^+$, 31), 354 ($[\text{M} - \text{OH}]^+$, 12); HRMS (ESI+): $[\text{M} + \text{H}]^+$, found 372.1918. $\text{C}_{20}\text{H}_{26}\text{N}_3\text{O}_4$ requires 372.1918.




((2S,6S,8S)-8-(1-(3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)-1,7-dioxaspiro[5.5]undecan-2-yl) methanol (10g).


The *title compound* **10g** (8.9 mg, 99%) was prepared as a pale yellow oil from TBDPS-protected triazole **28g** (15.0 mg, 25.1 μmol) and $3\text{HF}\cdot\text{NEt}_3$ (2 x 70 μL , 2.79 $\mu\text{L}/\mu\text{mol}$) in anhydrous THF (590 μL) using Procedure B. Purification was carried out by flash chromatography using EtOAc-*n*-hexane (0%, 17% EtOAc/*n*-hexane to 33% *n*-hexane/EtOAc). $[\alpha]_{\text{D}}^{27}$ -29.9 (c 0.89 in CHCl_3); R_f (33% *n*-hexanes/EtOAc) 0.29; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 3389 (O-H), 2938 (C-H), 2871 (C-H), 1610 (C=C), 1596 (C=C), 1498 (C=C), 1224 (C-O), 1043 (C-O-C), 977, 755, 686; δ_{H} (400 MHz, CDCl_3) 1.30–1.44 (1H, m, 3-H_A), 1.46–1.74 (8H, m, 3-H_B, 4-H_A, 5-H_A, 9-H_A, 10-H and 11-H), 1.88–2.03 (1H, m, 4-H_B), 2.07–2.12 (3H, m, OH, 5-H_B and 9-H_B), 3.55 (1H, dd, $^2J_{\text{AB}}$ 11.4 and $^3J_{2-\text{CH}_2\text{O},2}$ 6.5, 2- $\text{CH}_A\text{H}_B\text{O}$), 3.67 (1H, dd, $^2J_{\text{AB}}$ 11.4 and $^3J_{2-\text{CH}_2\text{O},2}$ 2.9, 2- $\text{CH}_A\text{H}_B\text{O}$), 3.82–3.87 (1H, m, 2-H), 3.88 (3H, s, PhOCH_3), 4.98 (1H, dd, $^3J_{8,9\text{ax}}$ 11.5 and $^3J_{8,9\text{eq}}$ 1.9, 8-H), 6.94–6.97 (1H, m, 4''-H), 7.25–7.28 (1H, m, 6''-H), 7.34 (1H, t, $^4J_{2'',4''}$ and $2'',6''$ 2.2, 2''-H), 7.40 (1H, t, $^3J_{5'',4''}$ and $5'',6''$ 8.2, 5''-H), 7.90 (1H, s, 5'-H); δ_{C} (75 MHz, CDCl_3) 18.2, 18.7 (2 x CH_2 , C-4 and C-10), 26.4 (CH_3 , C-3), 30.8 (CH_2 , C-9), 35.0, 35.3 (2 x CH_2 , C-5 and C-11), 55.6 (CH_3 , PhOCH_3), 65.0 (CH , C-8), 66.2 (CH_2 , 2- CH_2O), 70.0 (CH , C-2), 96.7 (C, C-6), 106.4 (CH , C-2''), 112.5 (CH , C-6''), 114.5 (CH , C-4''), 119.0 (CH , C-5'), 130.4 (CH , C-5''), 138.4 (C, C-1''), 150.7 (C, C-4'), 160.6 (C, C-3''); MS m/z (ESI+, MS_2^+ (360)) 360 ($[\text{M} + \text{H}]^+$, 1%), 342 ($[\text{M} - \text{OH}]^+$, 9), 314 (8); 256 (6), 204 (6), 186 ($[\text{M} + \text{H} - \text{C}_2\text{HN}_3\text{PhOCH}_3]^+$, 100), 173 (4); HRMS (ESI+): $[\text{M} + \text{H}]^+$, found 360.1909. $\text{C}_{19}\text{H}_{26}\text{N}_3\text{O}_4$ requires 360.1918.





((2S,6S,8S)-8-(1-(3-Nitrophenyl)-1H-1,2,3-triazol-4-yl)-1,7-dioxaspiro[5.5]undecan-2-yl) methanol (10h)


The *title compound* **10h** (7.5 mg, 67%) was prepared as an amorphous, yellow solid from TBDPS-protected triazole **28h** (15.0 mg, 30.0 μmol) and $3\text{HF}\cdot\text{NEt}_3$ (2 x 80 μL , 2.67 $\mu\text{L}/\mu\text{mol}$) in anhydrous THF (710 μL) using Procedure B. Purification was carried out by flash chromatography using EtOAc-*n*-hexane (0%, 17% EtOAc/*n*-hexane to 40% *n*-hexane/EtOAc). Mp. 110–112 $^{\circ}\text{C}$; $[\alpha]_{\text{D}}^{26}$ -46.4 (c 0.75 in CHCl_3); R_f (40% *n*-hexane/EtOAc) 0.20; IR (film) $\nu_{\text{max}}/\text{cm}^{-1}$ 3403 (O–H), 2942 (C–H), 1536 (N=O), 1351 (N=O), 1042, 980; δ_{H} (300 MHz, CDCl_3) 1.29–1.44 (2H, m, 3–H_A and 5–H_A), 1.47–1.76 (6H, m, 3–H_B, 4–H_A, 9–H_A, 10–H_A and 11–H), 1.89–2.19 (4H, m, 4–H_B, 5–H_B, 9–H_B and 10–H_B), 3.56 (1H, dd, $^2J_{\text{AB}}$ 11.3 and $^3J_{2\text{-CH}_2\text{O},2}$ 6.6, 2–CH_AH_BO), 3.67 (1H, dd, $^2J_{\text{AB}}$ 11.3 and $^3J_{2\text{-CH}_2\text{O},2}$ 2.9, 2–CH_AH_BO), 3.80–3.88 (1H, m, 2–H), 5.01 (1H, dd, $^3J_{8,9\text{ax}}$ 11.6 and $^3J_{8,9\text{eq}}$ 2.2, 8–H), 7.74 (1H, t, $^3J_{5'',4''}$ and $5'',6''$ 8.2, 5''–H), 8.04 (1H, s, 5'–H), 8.20–8.23 (1H, m, 4''–H), 8.28–8.31 (1H, m, 6''–H), 8.59 (1H, t, $^4J_{2'',4''}$ and $2'',6''$ 2.1, 2''–H); δ_{C} (75 MHz, CDCl_3) 18.2, 18.6 (2 x CH₂, C–4 and C–10), 26.3 (CH₂, C–3), 30.9 (CH₂, C–9), 35.0, 35.2 (2 x CH₂, C–5 and C–11), 65.0 (CH, C–8), 66.2 (CH₂, 2–CH₂O), 70.1 (CH, C–2), 96.8 (C, C–6), 115.1 (CH, C–2''), 118.8 (CH, C–5''), 123.0 (CH, C–6''), 126.0 (CH, C–4''), 130.9 (CH, C–5''), 137.9 (C, C–1''), 148.9 (C, C–3''), 151.7 (C, C–4''); MS m/z (ESI+, MS₂+ (375)) 375 ([M + H]⁺, 62%), 357 ([M – H₂O]⁺, 100), 329 ([M – NO₂ + H]⁺, 27), 201, (13); HRMS (ESI+): [M + H]⁺, found 375.1650. C₁₈H₂₃N₄O₅ requires 375.1663.












































References

1. W. L. F. Armarego and D. D. Perrin, *Purification of Laboratory Chemicals*, 4th edn., Pergamon, Oxford, UK, 1997.
2. K. W. Choi and M. A. Brimble, *Org. Biomol. Chem.*, 2008, **6**, 3518-3526.
3. D. M. Podgorski, S. W. Krabbe, L. N. Le, P. R. Sierszulski and R. S. Mohan, *Synthesis*, 2010, 2771-2775.
4. (a) Y. S. Hon, S. W. Lin and Y. J. Chen, *Synth. Commun.*, 1993, **23**, 1543-1553;
(b) T. Veysoglu, L. A. Mitscher and J. K. Swayze, *Synthesis*, 1980, 807-810; (c) D. F. Taber and K. Nakajima, *J. Org. Chem.*, 2001, **66**, 2515-2517.
5. The % d.e. was determined by Mosher ester analysis. Given that the objective was to quickly evaluate a range of chiral reducing agents and determine the % d.e., the absolute stereochemistry at C-3 of **17** after asymmetric reduction was not determined.
6. L. Diaz, J. Bujons, J. Casas, A. Llebaria and A. Delgado, *J. Med. Chem.*, 2010, **53**, 5248-5255.
7. D. J. Atkinson, J. Sperry and M. A. Brimble, *Synlett*, 2011, 99-103.
8. (a) F. J. Radcliff, J. D. Fraser, Z. E. Wilson, A. M. Heapy, J. E. Robinson, C. J. Bryant, C. L. Flowers and M. A. Brimble, *Bioorg. Med. Chem.*, 2008, **16**, 6179-6185;
(b) B. W. Michel, A. M. Camelio, C. N. Cornell, M. S. Sigman, *J Am Chem Soc* 2009, **131**, 6076-6077.
9. J.-M. Lee, J. Kim, Y. Shin, C.-E. Yeom, J. E. Lee, T. Hyeon and B. M. Kim, *Tetrahedron: Asymmetr.*, 2010, **21**, 285-291.
10. P. R. Kym, K. E. Carlson and J. A. Katzenellenbogen, *J. Med. Chem.*, 1993, **36**, 1111-1119.
11. K. Barral, A. D. Moorhouse and J. E. Moses, *Org. Lett.*, 2007, **9**, 1809-1811.
12. A. T. Tran, K. M. Cergol, W. J. Britton, B. S. A. Imran, M. Ibrahim, A. J. Laphorn and R. J. Payne, *MedChemComm*, 2010, **1**, 271-275.